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1. Introduction 
 
1.1 The liver 
 
1.1.1 Functions of the liver 
 
The liver plays a major role in metabolism and has a variety of functions, including glycogen 
storage, decomposition of red blood cells, plasma protein synthesis, hormone production, and 
detoxification. The liver also performs and regulates a wide range of high-volume 
biochemical reactions, including synthesis and breakdown of small and complex molecules, 
many of which are required for normal vital functions (KNOLLE and GERKEN 2000; MATON 
et al. 1993; ROMER and PARSONS 1977). The liver is composed of several cell types with 
specialized functions (Figure 1). The biggest part of the cell mass is composed of hepatocytes 
which make up 90% of the whole organ. Furthermore, the liver contains an endothelial 
lining, which is distinguished by fenestrae or pores, tissue macrophages known as Kupffer 
cells, and mesenchymal cells known as hepatic stellate cells (HSC). The single cellular 
components of the liver are organized within the sinusoid with the subendothelial space of 
Disse separating the epithelium from the sinusoidal endothelium (Figure 1). In normal liver 
this space contains a basement membrane composed of a defined mixture of extra cellular 
matrix (ECM) molecules, forming a sensitive network. This structure provides a cellular 
support because of permitting unimpeded transport of solutes and growth factors through it. 
This low-density ECM is essential for allowing the surrounding cells to maintain their 
differentiated function (FRIEDMAN 2000). In the mouse the liver arises from the primitive gut 
between 8.5 and 9 days of gestation (E 8.5–9). Cell proliferation and functional 
differentiation result in the initiation of expression of liver-specific genes during liver 
development. The earliest marker of liver cell commitment is α-fetoprotein (AFP); its mRNA 
is first detected at E 8.5 in immature hepatoblasts and diminishes to undetectable levels in the 
adult (SHIOJIRI 1981). The primitive liver begins to produce other serum proteins, such as 
albumin and transferrin, around E 9.5 and E 13 (CASCIO and ZARET 1991; KRAEMER 1981). 
The induction of albumin increases in parallel with the decrease of AFP gene expression. 
These proteins are expressed by the liver during adult life and are classified as markers of a 
parenchymal hepatic cell. Following partial hepatectomy or hepatic necrosis, permanent 
regeneration of hepatic cells occurs and may be reflected in a rise of AFP in the blood 
(CASCIO and ZARET 1991; KRAEMER 1981; SHIOJIRI 1981; YEOH et al. 1988). AFP is 
synthesized in large amounts by the fetal liver and by certain malignant tumours, like germ 
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cell tumours and most notably hepatocellular carcinoma (HCC), but not by normal adult 
hepatocytes (GERBER et al. 1983). 
 
 
 
 
 
Figure 1. Cellular architechture of the normal liver. In the normal liver, hepatocytes are enclosed by a 
fenestrated endothelium. In the space of Disse are the hepatic stellate cells (blue), and Kupffer cells (purple) 
located in the sinusoidal lumen. Stellate cells getting activated during liver injury, thereby stellate cells started 
to proliferate and producte massive ECM, including fibrillar collagen (yellow). Reference: Friedman, S.L. and 
Arthur, M.J.P., 2002. Reversing hepatic fibrosis. Science and Medicine: 194-205.  
 
 
 
1.1.2 Hepatocytes 
 
Hepatocytes are polygonal epithelial cells with a size ranging from 20 to 30 µm. Hepatocytes 
are arranged in folded sheets, thereby facing the blood-filled sinusoids. The blood is 
separated from the surface of the hepatocytes by a layer of flattened endothelial cells that 
covers the side of each hepatocyte sheet. This formation builds a three-dimensional system 
and facilitates the synthesis, degradation, and storage of a number of substances. Hepatocytes 
have a crucial function in carbohydrate and lipid metabolism, secreting most of the protein 
found in blood plasma and are important mediators of the acute phase response (SCHWABE et 
al. 2006). Moreover, hepatocytes are connected with the lumen of the gut via a system of 
canaliculi and larger ducts, thereby secreting waste products and bile into the gut. 
Hepatocytes may also play a role in the uptake of endotoxin and its removal from the 
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systemic circulation through secretion into the bile (MIMURA et al. 1995; VAN BOSSUYT et al. 
1988). For fulfilling all these different and important functions hepatocytes are well equipped 
with a varying content of carrier (e.g. taurocholate)-, receptor- (e.g. Toll-like receptor (TLR) 
2 and TLR4) and channel proteins (e.g. Zonula Occludens (ZO-1) and occludin) 
(MATSUMURA et al. 2003).  
 
 
 
1.1.3 Intrahepatic bile duct epithelial cells (cholangiocytes) 
 
The intrahepatic bile ducts comprise a complex three-dimensional network of conduits within 
the liver lined by specialized epithelial cells denoted as cholangiocytes or intrahepatic bile 
duct epithelial cells. A major function of cholangiocytes is bile formation. This process 
requires the coordinated function of cholangiocytes and hepatocytes. The primary bile is 
considerably modified by the bile duct epithelium which secretes fluid, bicarbonate, chloride 
and immunoglobulin (Ig) A and reabsorbs glucose, bile acids, amino acids and electrolytes 
(BOYER 1996; MASYUK et al. 2002). Furthermore, cholangiocytes have the capacity to 
proliferate in response to endogenous or exogenous stimuli and actively participate in 
inflammatory and regenerative processes within the liver (HAN and ULEVITCH 2005; 
LAZARIDIS et al. 2004). Therefore, cholangiocytes are able to communicate broadly with 
other cell types, such as HSC, portal fibroblasts and inflammatory cells due to secretion of 
various peptides and inflammatory mediators such as interleukin (IL)-6, transforming growth 
factor-β2 (TGF-β2), platelet-derived growth factor (PDGF)- B chain, tumour necrosis factor-α 
(TNF-α) and nitric oxide (NO) (STRAZZABOSCO et al. 2000). Thus, activated cholangiocytes 
probably play an important role, not only in regenerative processes, but also in the 
progression of chronic liver damage (STRAZZABOSCO et al. 2000). 
 
 
 
1.2 Hepatocelluluar carcinoma (HCC) 
 
In 70–90% HCC develops on the background of chronic liver cirrhosis or inflammation. 
HCC is the third most common cause of cancer-related deaths worldwide. Thus, nearly 
600,000 patients are dying from this disease annually. Risk factors and aetiologies differ 
among geographical regions. In regions with a high incidence, the majority of HCCs are 
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related to HBV and HCV. In developed countries, beside to virus-related HCC, high 
consumption of alcohol as well as non-alcoholic fatty liver (alcoholic steatohepatitis (ASH) 
and non-alcoholic steatohepatitis (NASH)) disease are the prevalent causes (EL-SERAG and 
RUDOLPH 2007; PARKIN et al. 2005). 
Histological classification of HCC is not strictly regulated because of its various architectural 
and cytological pattern (ROCKEN and CARL-MCGRATH 2001). On cytological level, tumour 
cells of HCCs may show fatty or clear cell change, Mallory-Denk-bodies, globular hyaline 
bodies, pale bodies, pleomorphic cells, and sarcomateous changes, but HCCs often exhibit 
different cytological variants within the same tumour. The most important differential 
diagnosis of well-differentiated HCCs is the appearance of liver cell adenoma and dysplastic 
nodules (DNs). DNs are usually identified macroscopically and measure on average 15–20 
mm in greatest dimension. However, smaller DNs may be distinguished by colour or texture 
from the surrounding liver. Diagnosis can be achieved by the identification of bile production 
(approximately 50% of HCCs) and application of special stains such as reticulin staining 
(ROCKEN and CARL-MCGRATH 2001). The HCCs can be distinguished from other solid 
growing tumours among others by examining the production of bile, the expression of AFP, 
the canalicular expression pattern of biliary glycoprotein 1 as well as the presence of albumin 
mRNA (ROCKEN and CARL-MCGRATH 2001).  
 
 
 
1.3 Inflammation and Cancer  
 
In the 19th century Rudolf Virchow was one of the first scientists who examined a potential 
link between inflammation and cancer on the basis of observations that tumours often arose 
at sites of chronic inflammation. Epidemiological studies have shown that chronic 
inflammation plays an important role in developing various types of cancer. It is validated 
that infections and inflammatory responses are linked to 15–20% of all deaths from cancer 
worldwide. The origin of 90% of common cancers is associated with somatic mutations and 
environmental factors whereas a minority of all cancers are caused by germline mutations 
(Figure 2) (ANAND et al. 2008; BALKWILL and MANTOVANI 2001). 
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Figure 2. Different categories of inflammation in tumourigenesis and cancer. Chronic inflammation 
correlating with infections or autoimmune disease pomotes tumour development and can lead to the induction 
of oncogenic mutations, genomic instability, early tumour promotion, and enhanced angiogenesis. Long-lasting 
exposure to environmental irritants or obesity can also support low-grade chronic inflammation that precedes 
tumour development. This inflammatory response can improve neoangiogenesis, promote tumour progression 
and metastatic spread, initiate local immunosuppression, and additionally increases genomic instability. Cancer 
therapy might also mediate an inflammatory response by causing necrosis. Reference: Grivennikov, S.I., 
Greten, F.R. and Karin, M., 2010. Immunity, Inflammation, and Cancer. Cell 140: 883-899 
 
 
It is well established that inflammation and cancer are linked by two different ways: an 
extrinsic and an intrinsic one. Inflammatory or infectious conditions promoting the risk of 
cancer development in several organs (e.g. colon and liver) are regarded as extrinsic factors 
whereas the intrinsic one is activated by genetic modifications.  
The initiation of both pathways causes the activation of transcription factors, mainly nuclear 
factor-κB (NF-κB) and signal transducer and activator of transcription 3 (STAT3) in tumour 
cells. These transcription factors direct the production of cytokines and chemokines. In this 
microenvironment, cytokines are able to influence both anti-tumour immunity and cancer cell 
growth and survival (GRIVENNIKOV and KARIN 2008; SZLOSAREK 2003; VORONOV 2003; YU 
2007).  
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1.4 The role of NF-κB in hepatocarcinogenesis 
 
1.4.1 The canonical and non-canonical pathway of NF-κB activation 
 
NF-κB was first identified approximately 20 years ago as a transcription factor that binds to 
the intronic enhancer of the kappa light chain gene (the κB site) in B cells (HAYDEN and 
GHOSH 2004). Studies identified NF-κB as a major regulator of innate and adaptive immunity 
and inflammatory responses (BONIZZI and KARIN 2004; KARIN and GRETEN 2005; LI and 
VERMA 2002; RULAND and MAK 2003). Further studies examined the function of the 
immune system in response to pathogens to elucidate the mechanisms by which NF-κB 
controls the transcription of inflammatory genes. Thereby, all studies showed that 
dysregulation of NF-κB is associated with many diseases, including cancer, atherosclerosis, 
and diabetes which results in a wide interest in this transcription factor and in the signalling 
pathways which are tightly associated with its activity (BONIZZI and KARIN 2004; COURTOIS 
and GILMORE 2006; KARIN 2006; KARIN and BEN-NERIAH 2000; KARIN and GRETEN 2005). 
The canonical, or classical, pathway is one of the best studied NF-κB pathways (Figure 3). 
This signalling cascade is activated in response to a variety of inflammatory stimuli, 
including the pro-inflammatory cytokines TNF-α and IL-1, or the exposure to the bacterial 
endotoxin lipopolysaccharide (LPS) (BONIZZI and KARIN 2004; GHOSH and KARIN 2002; 
HAYDEN and GHOSH 2004). The canonical pathway is characterized by the rapid 
phosphorylation of IκBα (inhibitor of κB) through the IKK (IκBα-kinase) -complex and 
subsequent ubiquitin-induced degradation by the 26S proteasome (GHOSH and KARIN 2002). 
The IKK complex is composed of three subunits, two catalytic subunits IKKα and IKKβ 
(also known as IKK1 and IKK2) and a regulatory subunit called the NF-κB essential 
modifier (NEMO, also known as IKKγ) (YAMAOKA et al. 1998; ZANDI et al. 1997). Both, 
IKKα and IKKβ are able to phosphorylate IκB, whereas genetic experiments revealed that 
IKKβ is the major IκB kinase in the canonical pathway (BONIZZI and KARIN 2004; 
PASPARAKIS et al. 2006). Moreover, there was no direct catalytic domain responsible for IκB 
phophorylation found in the NEMO protein. On the other hand, NEMO is essential for the 
activation of the IKK complex, including adapter proteins such as TNF receptor associated 
factors (TRAF) and receptor interacting protein (RIP) as well as autophosphorylation and 
probably regulatory ubiquitination steps (Figure 3) (HACKER and KARIN 2006; HAYDEN and 
GHOSH 2008).  
The other NF-κB pathway is the non-canonical, or alternative pathway, activated by CD40-, 
lymphotoxin-β -receptors (LTβR) and B-cell-activating factor of the TNF family (BAFF) 
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(Figure 3) (BONIZZI and KARIN 2004; PERKINS 2003). Subsequently, activation of IKKα by 
the NF-κB inducing kinase (NIK) results in the formation of p52 from p100 (BONIZZI and 
KARIN 2004; PERKINS 2006). It has been proposed that the non-canonical pathway is 
regulated by the IKKα homodimers which are functionally independent of the larger IKK 
complex (BONIZZI and KARIN 2004). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. The classical (canonical) and the alternative (non-canonical) NF-κB signalling pathway. (A) The 
classical pathway is triggered by pro-inflammatory stimuli and genotoxic stress, including the following 
cytokines, such as TNF-α, IL-1, LPS; viruses; and DNA-damaging agents. This leads to the IKKβ- and NEMO-
dependent phosphorylation of IκBs, which results in their proteasomal degradation, and subsequently liberation 
of NF-κB dimers (which are mostly p50–REL-A dimers). (B) The alternative pathway is initiated by certain 
TNF family members and leads, in an IKKβ-and NEMO-independent manner, to the phosphorylation of p100 
by IKKα and the degradation of its carboxy-terminal half by the proteasome. This results in nuclear 
translocation of p52–REL-B dimers. Modified from Luedde et al., 2009. The role of NF-κB in hepatic disease 
models. In: Translational research in chronic liver diseases, Shaker Verlag Aachen, 57-89, 2009 
 
 
 
1.4.2 Classical NF-κB signalling by members of the TNF receptor family 
 
Most information of the classical NF-κB pathway was received by intensive studies of the 
TNF-α signalling pathway. The TNF receptor superfamily is involved in regulating 
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apoptosis, survival, differentiation and proliferation through the activation of NF-κB, c-JUN 
N terminal kinase (JNK), p42/44 mitogen-activated protein kinase (MAPK) and p38 MAP 
kinase (AGGARWAL 2003); TNF-α is one of the key activators of inflammation and canonical 
NF-κB signalling. The ligation of the TNFR1 induces receptor trimerization and recruitment 
of the adapter protein TNFR1-associated DEATH domain protein (TRADD) and (HSU et al. 
1996; MICHEAU and TSCHOPP 2003) to one or more TRAFs (ARCH et al. 1998). It has been 
shown that activation of NF-κB and JNK is only mediated by TRAF2, TRAF5 and TRAF6 
(Figure 4). Recent studies indicate that after TNF binding, TNFR1 translocates to lipid rafts 
(cholesterol- and sphingolipid-enriched membrane microdomains), in which it associates 
with the adaptor proteins TRADD, TRAF2, and the RIP1 forming the signalling complex I. 
RIP1 is required for NF-κB activation downstream of TNFR1 and generally serves as an 
adaptor that enhances IKK recruitment to the activated receptor through an interaction 
between polyubiquitinated RIP1 and NEMO  (EA et al. 2006; HACKER and KARIN 2006; 
LEGLER et al. 2003; MEYLAN et al. 2004; TING et al. 1996; WU et al. 2006). Thereby, 
TRAF2 seems to be the ubiquitin ligase responsible for K63-linked ubiquitination of RIP1 
(EA et al. 2006). The exact mechanism of IKK activation mediated by the binding of NEMO 
to the K63-linked polyubiquitin chains of RIP1 is still unknown (VALLABHAPURAPU and 
KARIN 2009). Beside the activation of NF-κB, induction of MAPKs plays also an important 
role in the homeostasis of the cell (CRAIG et al. 2008; HAGEMANN and BLANK 2001).  
Alongside the mediating of cell survival and pro-inflammatory signals through NF-κB and 
activator protein 1 (AP-1) the TNFR1 has also the ability to initiate cell death signalling 
pathways. This involves the binding of Fas-associated death domain protein (FADD) to 
TRADD and the subsequent recruitment of pro-cysteine-aspartic proteases (caspase) 8 by the 
TRADD–FADD complex, the so-called cytosolic death-initiating signalling complex (DISC) 
or complex II (complex I consist of TNFR1, TRADD, TRAF2 and RIP1) (MICHEAU and 
TSCHOPP 2003; SCHNEIDER-BRACHERT et al. 2004). Caspases and ubiquitination are crucial 
for the initiation of complex II (Figure 4). The polyubiquitinated form of RIP1 avoids the 
transition of the membrane-associated complex I to the cytosolic complex II (CHO et al. 
2009; HE et al. 2009). Subsequently, the autocatalytic activation of bound pro-caspase 8 
releases activated caspase 8, which initiates apoptosis through cleavage and activation of pro-
caspase 3 (which can be also activated among the cytochrome c-caspase 9 axis). 
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1.4.3 NF-κB function in liver carcinogenesis 
 
NF-κB regulates the transcription of various genes including those involved in immune and 
inflammatory responses, cell death and proliferation (HAYDEN and GHOSH 2004). In the last 
years, many studies were conducted to understand the complex function of this pathway in 
vivo. Thus, studies using the conditional knockout technology in mice to inactivate this 
pathway in certain tissues have highlighted the crucial function of NF-κB in linking innate 
immune responses and cytokine signalling to various pathological conditions that initially 
had not been associated with inflammation.  
Genetic experiments have also emphasized the important role of the IKK subunits in TNF 
mediated liver apoptosis. Karin and co-workers showed that hepatocyte-specific deletion of 
IKKβ (IKKβ∆hep) sensitizes mice to liver failure and apoptosis following Concavalin A 
(Con A) as well as Dimethlynitrosamine (DEN) administration (MAEDA et al. 2003; MAEDA 
et al. 2005). However, these mice developed normal with regard to healthy constitution, 
normal postnatal liver development and function. Indeed, LPS administration induced a 
similar degree of liver damage in IKKβ∆hep and WT mice (MAEDA et al. 2003). In line with 
these findings, Luedde and colleagues showed that mice injected with TNF-α or challenged 
with LPS did not sensitize the liver of either IKKβ∆hep or another mouse model, IKKβf/f-
Mx-Cre, which displayed efficient knockout of IKKβ in Kupffer cells, non-parenchymal and 
lymphoid cells after Cre-mediated recombination (LUEDDE et al. 2005). Additionally, the 
authors demonstrated that hepatocyte-specific deletion of IKKβ does not increase apoptosis 
rate upon challenge with Con A. This stands in clear contrast to the results of Karin and 
colleagues. However, activation of NF-κB signalling after pharmacological inhibition of 
IKKβ was not impaired after TNF-α stimulation. Thus, the authors supposed that TNF-α 
induced activation of NF-κB in adult liver could appear independently of IKKβ.  
The knockout of Nemo in hepatocytes resulted in a complete blockage of TNF induced NF-
κB activation, which correlates with massive hepatocyte apoptosis in isolated hepatocytes 
and acute liver failure in vivo in reponse to LPS injections (LUEDDE et al. 2005; LUEDDE et 
al. 2007). Taken together, these results support that each single IKK subunit might have 
differential functions in the adult liver. 
Moreover, recent genetic studies in mice revealed new insight into the role of NF-κB 
signalling in the development of hepatocarcinogenesis (LUEDDE et al. 2007; MAEDA et al. 
2005; PIKARSKY et al. 2004). These studies showed impressively that the function of NF-κB 
might differ, depending on the stage of tumorigenesis, on the activation level of NF-κB and 
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in particular on the hepatic cell type (parenchymal vs. non-parenchymal cells) in which NF-
κB is active or inhibited. Pikarsky and colleagues studied the role of the NF-κB pathway in 
mdr2-knockout mice and showed that these animals spontaneously developed a cholestatic 
hepatitis caused by a defective biliary transport and that these mice subsequently developed 
HCCs. They demonstrated that inhibition of NF-κB by a hepatocyte specific inducible IκB 
superreppressor transgene results in a dramatic reduction of tumour development. Moreover, 
inhibition of NF-κB did not influence hepatocyte alteration and initiation of HCCs in this 
model, while later stages of tumour promotion are a characteristic aspect of the observed 
phenotype. Finally, the authors assumed that NF-κB functions as a hepatic tumour promoter 
which is reqiured during later stages of tumour promotion to avoid TNF induced apoptosis of 
the transformed liver cells. 
Contrary to this study, Luedde et al. and Maeda et al. in 2005 demonstrated that NF-κB has a 
tumour-suppressive role in the liver during the early steps of tumour initiation. Furthermore, 
mice with hepatocyte-specific deletion of Nemo develop spontaneous hepatitis at young age, 
and subsequently multiple liver tumours (LUEDDE et al. 2007).  
Thus, further genetic and preclinical studies are needed for a better understanding of the role 
of NF-κB, to obtain more information about the pathway and potential binding partners. 
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Figure 4. TNFR mediated NF-κB activation and apoptosis. Following TNF-α binding, the trimeric TNFR 
binds to TRADD, which recruits TRAF2/5, RIP1 to form complex I. RIP1 ubiquitination occurs in the complex 
I,, thus recruiting and activating TAK1 and the IKK complex. Additionally, RIP1, TRAF2 and TRADD became 
modified and dissociate from the receptor. Then, TRADD and /or RIP bind to FADD, which then recruits 
caspase-8 to the complex II. Procaspase 8 is converted to caspase 8, which cleaves procaspase 3 into the mature 
effector caspase 3, to induce apoptosis. Reference: Bohj, V.G. and Chen, Z.J., 2009. Ubiquitylation in innate 
and adaptive immunity. Nature 458: 430-437 
 
 
 
1.5 Transforming growth factor-beta (TGF-β)-activated kinase 1 (TAK1) 
 
TAK1 is a serine /threonine kinase of the MAPK kinase kinase (MAP3K) family and was 
originally identified as a kinase involved in TGF-β-signalling (YAMAGUCHI et al. 1995). 
Different studies demonstrated that TAK1 is not only an evolutionally conserved protein it 
has also a critical function in antibacterial innate immunity (VIDAL et al. 2001). Furthermore, 
this was additionally confirmed by the deletion of Tak1 in mouse embryos, leading to early 
embryonic lethality at E 9.5 as a result of its regulatory function of several cytokine 
signalling pathways (SATO et al. 2005; SHIM et al. 2005). These findings revealed an 
important role for TAK1 in cell development and innate immunity. Based on these results, 
continuative work was done to evaluate the specific role of TAK1 by using different cell 
culture systems and by generating various conditional knock-out mice (LIU et al. 2006; LLUIS 
et al. 2010; SATO et al. 2005; YAMAZAKI et al. 2009). Recent studies revealed that TAK1 
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functions as an upstream signalling molecule of NF-κB and MAPKs in TNFR and TLR/IL-
1R signalling pathways (ADHIKARI et al. 2007). At this, activated TAK1 is recruited to 
TRAF6 and TRAF2 complexes in response to TNFR and TLR/IL-1R stimulation, 
respectively. Thereby, TAK1 forms a complex with its association partners, TAB1, TAB2 
and TAB3 (WANG et al. 2001). This activated TAK1 complex is able to phosphorylate 
members of the Mitogen-activated protein kinase kinase (MKK) family and IKKs, leading to 
the activation of JNK and p38MAPK and NF-κB. It has been proposed that TRAF6-mediated 
K63-linked polyubiquitination is required for the activation of TAK1 (ADHIKARI et al. 2007). 
Additionally, it was shown, that the TAK1/TAB1 complex, which has the ability to 
phosphorylate other MKKs thereby activating JNK and p38MAPK, is not sufficient to 
activate the IKK complex (WANG et al. 2001). Consequently, TAB2/3, but not TAB1, is 
nessecary for IKK activation by TRAF6 in vitro (ADHIKARI et al. 2007). 
The fact that TAK1 is involved in all of these important pathways underline the crucial role 
of TAK1 to trigger cellular responses in regard to growth factors, cytokines or stress. 
 
 
1.6 Aim of the study 
 
There is raising evidence that chronic inflammatory processes are involved in mediating 
tumour development. During this process several cytokines, such as IL-1, Il-6 and TNF-α are 
mainly involved in promoting tumour growth and are encoded by target genes of the NF-κB 
pathway. 
The TNF signalling cascade is one of the best studied and most important pathways involved 
in the pathogenesis of a variety of liver diseases. Initiation of the TNF signalling cascade 
normally leads to NF-κB activation, thereby mediating immunological and inflammatory 
responses. The study by Lüdde in 2007 showed that conditional deletion of NEMO in liver 
parenchymal cells leads to spontaneous liver damage, hepatitis, liver fibrosis, hepatosteatosis 
and the development of HCC. Based on these findings and that several studies demonstrated 
that JNK, p38 and NF-κB might co-regulate apoptosis and HCC development, we had the 
hypothesis that upstream molecules like an upstream MAP3K might have an even more 
fundamental role in liver cancer formation.  
Previous studies revealed that constitutive deletion of Tak1 in mouse embryos leads to early 
lethality. These animals died at E 9.5 as a result of TAK1’s regulatory function of numerous 
cytokine signalling pathways. Furthermore, recent studies revealed that TAK1 is upstream 
located in the TGF-β, TNFR and in the TLR/IL-1R pathway, playing a crucial role in the NF-
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κB activation. Under specific conditions TAK1 is able to induce apoptosis by mediating 
activation of JNK and p38 via phosphorylation of the MAP2Ks MKK4/7 and MKK3/6.  
Here, we aimed at assessing if the deletion of TAK1 has a significant impact on 
proinflammatory and proapoptotic pathways in liver which possibly results in the 
development of a spontaneous phenotype. Moreover, to clarify the specific function of TAK1 
in liver we compared our results with the ones of the NEMOLPC-KO phenotype.  
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2. Materials and Methods 
 
2.1 Chemicals 
 
Name         Company 
 
Ammonium persulfate (APS)     MP Biomedicals 
Acetone        Pharmacy  
University Hospital Aachen 
Agarose (Ultra pure)       Invitrogen 
Acetic acid (glacial) 100%      Merck 
5-Bromo-2’-deoxyuridin (BrdU)     Applichem 
Bromphenolblue       Merck 
Boric acid        Applichem 
Citric acid        Merck 
Chloramine-T        Sigma-Aldrich 
DTT (Dithiotreitol)       Roth 
4-dimethylaminobenzaldehyde (Ehrlich’s reagent)   Merck 
EDTA (N,N,N′N′-Ethylendiamintetraacetate)   Applichem 
EGTA         Fluka 
(Ethylenglykol-bis(aminoethylether)-N,N,N′N′-tetraacetate 
Ethanol (absolute)       Applichem 
Ethidiumbromide       Roth 
Ficoll PM 400        GE Healthcare 
Formaldahyde (37%)       Roth 
Glutaraldehyde (25%)      Roth 
Glycerol        Serva 
Hydrochloric acid (HCl; 37%)     Applichem 
HEPES         Roth 
(2-(4-(2-Hydroxyethyl)-1-piperazinyl)-ethansulfonacetate) 
Isopropyl alcohol       Applichem 
Magnesium chloride (MgCl2)     Merck 
β-Mercaptoethanol       Sigma 
Methanol        VWR Prolabo 
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Name         Company 
NEB-buffer 2        New England BioLabs 
Nonidet P-40 (NP-40)      Fluka 
Paraformaldehyde (PFA)      Roth 
Perchloric acid       Merck 
Ponceau Red        Sigma-Aldrich 
Potassium chloride (KCl)      Merck 
SDS (Pellets)        Roth 
Sodium acetate       Merck 
Sodium chloride (NaCl)      Applichem 
Sodium hydroxide (NaOH)      Applichem 
Sodium hydrogen carbonate (NaHCO3)    Sigma-Aldrich 
Sodium dihydrogen phosphate (NaH2PO4)    Merck 
Disodium hydrogen phosphate (Na2HPO4)    Merck 
Trisodium citrate       Sigma-Aldrich 
TAE-Buffer (50x)       Applichem 
TEMED (N,N,N′N′-Tetramethylethylendiamine)   Roth 
Tris         Applichem 
Triton X-100        Serva 
Tween-20        Serva 
 
 
2.1.1 Radiochemicals 
 
32P-γ-ATP        Hartmann Analytic 
 
 
2.2 Instruments and equipment 
 
Biophotometer (Spectrophotmeter)     Eppendorf 
Cell culture centrifuge 1.0R      Heraeus 
Cell culture flow       Gelaire 
Cell culture incubator       Heraeus 
Centrifuge 5415R       Eppendorf 
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Name         Company 
Cooling centrifuge 5417R      Eppendorf 
Cryostat HM 550       Microm 
FACS Canto II Analyzer +BD FacsDiva Software   Beckton Dickinson 
Gel dryer        Biometra 
Incubator ONYX 2000      Hermle Labor Technik 
LAS-4000 Mini Imager      Fujifilm 
Liquid scintillation counter 1219 Rack Beta LKB   Wallac 
Perfusion pump (Masterflex L/S)     Cole Parmer 
pH-meter        Mettler Toledo 
Power supply        GE Healthcare 
7300 Real-Time PCR-System     Applied Biosystems 
+Sequence Detection Software Version 
SDS PAGE electrophoresis  Amersham Biosciences 
Thermocycler T3000 and Tpersonal     Biometra 
Thermomixer 5436       Eppendorf 
Tissue homogenizer (cone-shaped)     VWR 
UV transilluminator (GelDoc 2000)      Biorad 
Vacuum pump       Büchi 
Water bath        GFL 
Weighing machine       Sartorius 
 
 
2.3 Consumables 
2.3.1 General material 
 
Amersham HyperfilmECL      GE Healthcare 
Eppendorf tubes (safe lock, 1 ml and 2 ml)    Eppendorf 
Falcon tubes (15 ml and 50 ml)     BD Falcon 
Minisart SRP4 (syringe filter)     Sartorius 
Nitrocellulose Membrane      Schleicher & Schüll 
ProbeQuant™ G-50 Micro Column Nick-spin-column  GE Healthcare 
PVDF membrane (Immobilon)     Millipore  
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Name          Company 
Scintillation tubes Pony vial™      Packard 
Scintillation fluid Ultima Gold™XR     Packard 
Super frost slights®        Roth 
Whatman paper        VWR 
SuperScript III First-Strand Synthesis System     Invitrogen 
T4-Kinase buffer (10x)       NewEngland  
BioLabs 
Trizol         Invitrogen 
TUNEL kit         Promega 
(Terminal deoxynucleotidyl transferase dUTP Nick End Labelling) 
 
 
2.3.2 Material for animal experimentation 
 
Catheter with injection port (Bivalve®20G; 1.0x32mm)   Vygon 
Disposable Scalpels sterile No. 10 and11     Feather 
General chow for animals       Altromin 
Glas capillaries        Hilgenberg 
Injection needles (Stericane® Gr.17; 24Gx25mm; 0.4mmx12mm)  Braun 
Isofluran (Forene®)        Abott 
Ketamin (10%)        CEVA 
Lipopolysaccharide (LPS)       Sigma-Aldrich 
NaCl (0.9%) irrigation solution      DeltaSelect 
Surgical instruments        F.S.T 
Syringe Omnican®        Braun 
Syringe Discardit II (2, 5, 10, 20 ml)     Beckton Dickinson 
Xylazin/Rompun (2%)       medistar 
 
 
2.3.3 Material for cell culture  
 
Cell strainer with 70µm nylon mesh      BD Falcon 
Cell scraper         BD Falcon 
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Name          Company 
Cell culture plates (6-and 24 well)      BD Falcon 
Collagenase Type IV        Worthington 
DMEM (high Glucose)       PAA 
EBSS (w/o Mg and Ca)       PAA 
EBSS (with Mg and Ca)       PAA 
EDTA          Applichem 
EGTA          Fluka 
Fetal Calf Serum (FCS)        PAA 
L-Glutamin         Gibco 
PBS (10x), pH7.4        PAA 
Penicillin/Streptomycin (P/S)      Gibco 
Petri dish         Sarstedt 
TNF (murine, recombinant)       Hiss 
Trypan blue stain         Gibco 
 
 
2.4 Analytical chemicals, reagents and kits 
 
30% Acrylamid/Bis Solution, 37, 5:1 (2.6% C)    Biorad 
AmershamECL plus Western blot detection system   GE Healthcare 
Aprotinin         Applichem 
Bovine Serum Albumin (BSA)      PAA 
Complete Mini® (Protease Inhibitor Cocktail Tablets)   Roche 
Covering solution for cryo sections (Tissue-Tek®)    Sakura 
DEPC treated water        Ambion 
DirectPCR Lysis reagent (Tail lysis buffer)     Euromedex 
DNA Ladder          Invitrogen 
DNA Taq Polymerase (5U/µl)      Invitrogen 
dNTP-Mix (for PCR)        Invitrogen 
EDTA (25 mM)        Invitrogen 
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Name         Company 
Fish-Gelatine        Sigma-Aldrich 
MgCl2 (for PCR)       Invitrogen 
Mounting Medium Vecta Shield®     Vector 
Novex Presharp (Rainbowmarker)     Invitrogen 
Pefablock        Roche 
PhosSTOP (Protease inhibitor Cocktail Tablets)   Roche 
Poly dIdC      Amersham Biosciences 
Protein A Agarose Beads      Roche 
RestoreWestern blot stripping buffer    Thermo scientific 
Rnase away        Molecular Bio Products 
RNeasy Mini kit        Qiagen 
 
 
2.5 Enzymes 
 
DNA Taq-Polymerase (5U/µl) (+10xPCR-MgCl2 buffer)  Invitrogen 
Proteinkinase K       Roche 
SYBR®GreenER qPCR SuperMix     Invitrogen 
Collagenase Type IV       Worthington 
Trypsin Inhibitor (Type II-S: Soybean)    Sigma-Aldrich 
T4-Polynucleotid kinase      New England BioLabs 
 
 
2.6 Antibodies 
2.6.1 Non-labeled primary antibodies 
 
A6 (1:50)        kindly provided by Dr.  
V. Factor; Zurich, 
Switzerland 
AKT (1:1000)        Cell signaling Technology 
Phospho-AKT (1:2000)      Cell signaling Technology 
Anti-Bromodeoxyuridine (BrdU) (1:200)    Chemicon Int. 
CK19 (1:500)        Santa Cruz Biotechnology 
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Name         Company 
cleaved Caspase 3 (1:5000)      Cell signaling Technology 
Collagen IV (1:50)       Ventana (iVIEW DAB kit) 
Cyclin D1 (72-13G) (1:1000)     Santa Cruz Biotechnology 
Cyclin E1 (1:1000)       Santa Cruz Biotechnology 
FOXO3a (1:1000)       Cell signaling Technology 
Phospho-FOXO3a (1:1000)      Cell signaling Technology 
GAPDH (1:1000)       ABD Serotec 
IκBα (1:1000)        Cell signaling Technology 
Phospho-IκBα (SER32/36) (5A5) (1:1000)    Cell signaling Technology 
IKKγ (FL-419)       Santa Cruz Biotechnology 
SAPK/JNK (56G8) (1:1000)      Cell signaling Technology 
Phospho-SAPK/JNK (Thr183/Tyr185) (81E11) (1:1000)  Cell signaling Technology 
Ki-67 (1:200)        NeoMarkers 
Phospho-SEK1 / MKK4 (1:1000)     Cell signaling Technology 
Phospho-MKK7 (1:1000)      Cell signaling Technology 
Pan-Cytokeratin (1:500)      DAKO 
PCNA (1:2000)       Zymed 
Smad2/3 (1:1000)       BD Biosciences 
Phospho-Smad3 (1:200)      Cell signaling Technology 
TAK1/MAP3K7 (1:1000)      IMGENEX 
Phospho-TAO2 (1:1000)      Thermo sciences 
p38 MAP Kinase (1:1000)      Cell signaling Technology 
Phospho-p38 MAPK(Thr180/Tyr182) (3D7) (1:1000)  Cell signaling Technology 
p42/44 MAP Kinase (ERK) (1:1000)    Cell signaling Technology 
Phospho-NF-kB p65 (Ser536) (93H1) (1:1000)   Cell signaling Technology 
 
 
2.6.2 Supershift Antibodies 
 
p50 (NLS) x (2µg/µl)       Santa Cruz Biotechnology 
p65 (A) x     (2µg/µl)       Santa Cruz Biotechnology 
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2.6.3 Secondary antibodies 
2.6.3.1 HRP-conjugated antibodies 
 
Name         Company 
ECL anti-rabbit IgG      GE Healthcare 
ECL anti-mouse IgG      GE Healthcare 
 
 
2.6.3.2 Secondary antibodies for fluorescence microscopy 
 
Alexa Fluor 594 goat anti mouse     Invitrogen 
Alexa Flour 488 goat anti rabbit     Invitrogen 
 
 
2.7 Animals 
2.7.1 Animal breeding 
 
All mouse strains were housed in Macrolon® cages providing food and water ad libitum and 
were grouped up to 10 animals per cage. During breeding and following experiments the 
cages were placed in a specific pathogen-free facility (S1 area) of the University Hospital 
Aachen in a temperature-controlled room (20-24ºC and humidity of 50-60%) with 12 hours 
light-dark rhythm. All experiments were done accordingly to the agreement of, the German 
legislation on protection of animals and the National Institutes of Health ‘Guide for the Care 
and Use of Laboratory Animals’ (Institute of Laboratory Animal Resources, National 
Research Council; NIH publication 86-23 revised 1985). 
 
 
2.7.2 Generation of conditional knockout mice  
 
The Cre recombinase of the P1 bacteriophage is a member of the integrase family of site-
specific recombinases. It is a 38 kD protein that catalyzes the recombination between two of 
its recognition sites, termed loxP (HAMILTON and ABREMSKI 1984). This Cre-loxP 
recombinase system is the most broadly used technique to generate conditional knockout 
models. Thus two genetically modified mouse lines are required for a recombinase dependent 
conditional experiment. At a specific stage of embryonic or postnatal development one mouse 
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line expresses the recombinase (e.g. Cre) in selected cell lineages or tissues. Another line 
carries the conditional allele, a gene segment (or the entire gene) flanked by two recognition 
target sites (here loxP). After intercrossing, cells expressing the recombinase delete or modify 
the conditional allele in offspring. By contrast, the target gene remains intact and functional in 
the cells of all other tissues where the recombinase is not expressed. Thus, the function of the 
target gene can be studied in the cell or tissue type of interest at a specific time (KWAN 2002). 
 
 
2.7.2.1 Hepatocyte-specific knockout of TAK1 and NEMO  
 
To investigate the hepatic function of TAK1 and NEMO in vivo, mice with conditional 
deletion of the Tak1 and Nemo- gene in liver parenchymal cells (LPC) were generated. Mice 
carrying loxP-site-flanked (floxed) alleles of the TAK1 gene Map3k7 (Tak1Fl) (SATO et al. 
2005) and the Nemo gene (NemoFl) (BERAZA et al. 2009) were crossed to Alfp-cre transgenic 
mice (KELLENDONK et al. 2000) to generate a liver parenchymal cell-specific knockout of the 
respective genes (TAK1LPC-KO, NEMOLPC-KO). In all experiments, littermates carrying the 
respective loxP-flanked alleles but lacking expression of Cre-recombinase were used as wild-
type (WT) controls. Mice were bred on a mixed C57/BL6-SV129Ola genetic background. 
Only sex-matched animals were compared. 
 
 
2.7.2.2 Genotyping of knockout mice 
 
To determine the correct genotype of the different mouse strains, tail biopsies were collected, 
DNA isolated and analysed by PCR (as described in Chapter 2.8.3.1)  
 
 
2.7.3 Application techniques for drugs and other substances in mice  
2.7.3.1 Injection of substances intraperitoneal (i.p.) 
 
For i.p. injection the mouse was fixed at the neck and tail with one hand and application 
occurred in dorsal direction. 
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2.7.3.2 Liver injury model 
 
Liver injury experiments were performed on 6 to 8 week old mice. Following i.p. 
administration of LPS (25µg/10g body weight) mice were sacrificed after 30 minutes, 1, 2, 8, 
and 10 hours. The liver and the blood serum were analysed as described below. 
 
2.7.4 Assessment of blood and liver tissue samples 
2.7.4.1 Rodent retro-orbital bleeding 
 
Blood withdrawal occurred by penetrating the retro-orbital sinus with a glass capillary. The 
venous blood was collected in a serum tube and was centrifuged at 5000 rpm, 4ºC and for 5 
minutes. Serum was transferred into an Eppendorf tube and stored at-20ºC. Serological 
analyses of different parameters were performed by the clinical routine laboratories of the 
Institute of Clinical Chemistry and Pathobiochemistry, University Hospital Aachen. 
 
 
2.7.4.2 Withdrawal and handling of the liver 
 
The killed animal was fixed on a styrofoam plate. The abdominal cavity was cut open along 
the Linea alba and the extraction of the complete liver occurred by dividing the ligaments. 
The liver was cleaned in ice-cold PBS and afterwards in fresh ice-cold PBS photographed. 
The largest liver lobe, lobus hepaticus dexter, was removed and fixed in 4% PFA/PBS for 24-
48 hours and embedded in paraffin. From this paraffin block 4-7µm sections were performed 
and subsequently stained with H/E, Sirius Red and Reticulin following routine protocols. 
From every single liver lobe a small piece of tissue was dissected and embedded in Tissue -
Tek® to perform cryo-sections for immunohistochemical stainings following standard 
protocols. The remaining liver tissue was cut in little pieces, shock frosted in liquid nitrogen 
and stored in Eppendorf tubes by -80ºC. 
 
 
2.7.5 Isolation of primary hepatocytes 
 
The perfusion system was cleaned with 70% Ethanol, rinsed with PBS and subsequently 
equilibrated with Solution I. Mice were narcotised as described below. The mouse was fixed 
with tape on all four limbs on a styrofoam plate. The abdominal cavity was cut open along the 
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Linea alba and two cuts were placed above the femur along the lateral abdominal walls to 
facilitate the outflow of the blood and the enzymatic solution during the perfusion of the liver. 
The intestine was moved aside with a sterile cotton applicator, thereby exposing the vessels. 
The Vena portae was cannulated with a 20-gauge catheter. The catheter was rinsed with 
Solution I to avoid air bubbles in the perfusion system. The tube was connected with the 
injection port and rinsed with solution I while the Vena cava inferior was dissected. The 
perfusion pump was set to a rate of 5 ml per minute. After 5 minutes of perfusion the liver 
was perfused with solution II for 15 minutes. The liver was removed and stored in ice-cold 
EBSS buffer. The next part of the isolation was done under sterile conditions. The liver was 
transferred into a Petri-dish with ice-cold EBSS. The capsule of the liver was disrupted using 
a forceps and cell scraper. The hepatocytes were separated with a cell strainer (mesh size 70 
µm) and centrifuged at 500 rpm, for 2 minutes and 4ºC. The pellet was washed three times 
with 20 ml DMEM medium containing 10% BSA, 1% P/S and 1% L-Glutamine. The viability 
of hepatocytes was determined by trypan blue staining. The cells were confluent disseminated 
on 10 cm petri-dishes and cultured in DMEM medium at 37ºC in a humidified atmosphere of 
95% air and 5% CO2. After 4 hours survival and adhesion of the cells were controlled. The 
hepatocytes were used for experiments in the next 24-30 hours. 
 
 
Anaesthesia    
Ketamin (10%)   450 µl 
Rompun (2%)      50 µl 
NaCl (0.9%) add      5 ml 
 
Buffers and media   additives    volume 
Solution I    EBSS w/o Ca and Mg   50 ml 
     EGTA (0.5 M)     50 µl 
 
Solution II    EBSS with Ca and Mg   50 ml 
     Hepes (10mM), pH 7.4  1.19 g 
     Collagenase II    15 mg 
     soybean trypsin inhibitor    2 mg 
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DMEM    FCS 10%     50 ml 
     P/S    1%       5 ml 
     L-Glutamin 1%      5 ml 
 
 
2.7.5.1 Stimulation of primary hepatocytes with TNF 
 
To investigate proinflammatory signalling cascades in vitro, primary hepatocytes were 
stimulated with recombinant murine TNF (10ng/ml). The cells were stimulated and 
afterwards washed twice and harvest in ice-cold PBS. The hepatocytes were transferred in 
Eppendorf tubes and centrifuged at 6.000 rpm, for 1 minute and 4ºC. The supernatant were 
discarded and the pellets were immediately shock frosted in liquid nitrogen and stored by  
-80ºC. 
 
 
2.8 Biomolecular methods 
2.8.1 Isolation and analysis of proteins 
2.8.1.1 Isolation of proteins from whole liver extracts 
 
A deep-frozen piece of liver tissue was homogenized in 500-800µl of ice-cold NP-40-Lysis-
Buffer using a con-shaped tissue homogenizer. The liver suspension was transferred into an 
Eppendorf tube and centrifuged at 10.000 rpm, for 10 minutes and 4ºC. Afterwards the 
supernatant was transferred into a new Eppendorf tube and its protein concentration was 
measured by the Bradford protein assay. The protein concentration was adjusted to 6µg/µl. 
 
Buffers     additives     volume 
NP-40-Lysis buffer   1M Tris-HCl (pH 7.5)    25 ml 
     5M NaCl      15 ml 
     NP-40      2.5 ml 
     ddH2O                 ad 500 ml 
Freshley added: 
2×1 tablette of Complete Mini and PhosSTOP were dissolved in 1 ml ddH2O 
(Proteaseinhibitor-Mix) 
1 ml of Proteaseinhibitor-Mix, 100µl of 0.1 M Pefablock and 10µl of 1 M DTT was added to 
9 ml of NP-40-Lysis-Buffer 
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2.8.1.2 Isolation of cytoplasma- and nuclear proteins from liver tissue/ cell lysate 
 
A deep-frozen piece of liver tissue/cell pellet was homogenized as described above and 
incubated in 50-800µl buffer A for 10 minutes on ice (swelling step). Afterwards 3.5µl (per 
50µl used buffer A) NP-40 (10%) was added, mixed well and incubated for 1 minute at 4°C 
(lysis step). The cell suspension was centrifuged at 10.000 rpm, for 1 minute and 4ºC. The 
supernatant (cytoplasmic fraction) was recovered and transferred into a new Eppendorf tube 
and its protein concentration was calculated by the Bradford protein assay. The pellet was 
redissolved in 50-200µl buffer A (w/o NP-40) and centrifuged for 15 seconds at full speed at 
4°C (washing step to remove detergent). The supernatant was discarded. The pellet was 
resuspended in 15-75µl buffer C and incubated for 30 minutes (extraction step); during this 
time the pellet was resuspended 2-3 times. Subsequently, the cell suspension was centrifuged 
at 10.000 rpm, 10 minutes and 4ºC. The supernatant was aliquoted into Eppendorf tubes and 
stored by -80ºC. Measurement of protein concentration occurred by the Bradford protein 
assay. 
 
Buffers     additives    volume 
Buffer A    10 mM Hepes pH 7.6   0.48 g 
10 mM KCl     0.15 g 
2 mM MgCl2     0.08 g 
→ added and dissolved in 180 ml a.dest. 
0.1 mM EDTA   40 µl added 
Buffer C    50 mM Hepes pH 7.8   1.19 g 
50 mM KCl     0.37 g 
300 mM NaCl    1.80 g 
→ added and dissolved in 80 ml a.dest. 
0.1 mM EDTA    20µl added 
10% Glycerol    10 ml added 
and mixed well 
 
10% NP-40    1 ml NP-40 (conc.) dissolved in 9 ml a.dest. 
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Freshley added: 
2×1 tablette of Complete Mini and PhosSTOP were dissolved in 1 ml ddH2O 
(Proteaseinhibitor-Mix) 
2×1 ml of Proteaseinhibitor-Mix was added to 9 ml of buffer A and buffer C  
100µl of 0.1 M Pefablock and 10µl of 1 mM DTT was added to each buffer, finally. 
 
 
2.8.1.3 Bradford protein assay 
 
The Bradford assay is a colorimetric protein assay and is based on an absorbance shift in the 
dye Coomassie when its previously red form changes and stabilizes into its blue form during 
the binding of proteins (Coomassie binds to arginine and aromatic amino acids). The bound 
form of the dye has an absorption spectrum of 594 nm. And thereby the increase of 
absorbance at 594 nm is proportional to the amount of bound dye, and thus to the amount 
(concentration) of protein present in the sample (BRADFORD 1976; NOBLE 2009; ZOR 1996). 
A BSA standard curve was performed and the linear regression estimated. The Bradford 
reaction solution was diluted 1:5 in distilled water; 998µl of Bradford solution were 
transferred in each cuvette and 2µl of protein sample was added and mixed gently (at high 
protein concentrations 2µl of a 1:5 or 1:10 dilution of the protein sample was used). After 15 
minutes of incubation the samples were measured at 594nm by using a spectrophotometer. 
The protein concentration of each sample was calculated on the basis of the BSA standard 
curve in Excel.  
 
 
2.8.2 Investigation of proteins  
2.8.2.1 Western-Blot (SDS-PAGE) 
 
The Western blot analysis is the most common technique to identify proteins in a tissue 
homogenate or extract. Protein samples were boiled at 95ºC for 5 minutes and concentrations 
of finally 60µg were loaded on a 10% SDS/polyacrylamide gel (normally 8-12%, depending 
on the molecular weight of the expected proteins). Electrophoretic separation occurred at 120 
V in SDS running buffer for 2.5 hours. Afterwards the proteins were transferred to a PVDF 
membrane (activation of the membrane: 15 seconds Methanol, 2 minutes a. dest. and 5 
minutes Towin-transfer buffer) using a semi-dry blotting chamber at 160 mA for 1.5 hours. 
Subsequently, the quality of the protein transfer to the PVDF membrane was proved by 
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Ponceau Red staining. The membrane was blocked in TBS-Tween (0.1%) containing 5% of 
non-fat dry milk for 1 hour at room temperature. Then, the membrane was incubated over 
night with the primary antibody solution (dilution according to the provider’s 
recommendation) under gentle agitation at 4ºC. The blot was washed three times with TBS-
Tween (0.1%), eliminating unbound primary antibody, then exposed to a secondary HRP-
conjugated antibody for 1 hour at room temperature under mild agitation. Subsequently, the 
membrane was washed again three times with TBS-Tween (0.1%) to eliminate unbound 
secondary antibody. The membrane was incubated with enhanced chemiluminescent (ECL) 
solution for 5 minutes and exposed to an ECL-Hyperfilm (alternative method: membrane 
exposed to a LAS mini developing machine from Fujifilm).  
 
Buffer      additives    volume 
SDS running-buffer (10x), 1 liter  250 mM Tris, pH 8.4     30.29 g 
192 mM Glycerol   144.13 g 
1% SDS           10 g 
→ ad 1liter a.dest. 
 
Towin transfer buffer, 1liter   25 mM Tris       3.03 g 
190 mM Glycerol   14.26 g 
20% Methanol (v/w)    200 ml 
→ ad 1liter a.dest. 
→ pH~8.3-8.5  
(it is not necessary to determine the pH value) 
 
TBS-Tween (10x), 1 liter   0.2 M  Tris    24.2 g 
1.4 M NaCl     80.0 g 
→ pH 7.6 (determination with HCl) 
→ 1 ml Tween-20 added to 1 liter TBS buffer (1x) 
 
SDS sample buffer/     10 mM TrisHCl, pH 6.8  4.2 ml 
Lämmli buffer (5x), 10 ml   100% Glycerol   2.0 ml 
10% SDS    3.8 ml 
2-Mercaptoethanole   8.0 ml 
Bromphenolblue        ad libitum 
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Separating gel (1x)     8%  10%  12.5% 
dd H2O   4.6 ml  4.0 ml  3.28 ml 
Tris 1.5 M pH 8.8  2.5 ml  2.5 ml  2.50 ml 
Acrylamide   2.7 ml  3.3 ml  4.06 ml 
10% SDS   100 µl  100 µl    100 µl 
APS    100 µl  100 µl    100 µl 
TEMED           6 µl    7.5 µl      7.5 µl 
 
Stacking gel  dd H2O   3.10 ml 
1.5 M Tris pH 6.8  1.25 ml 
Acrylamide     0.5 ml 
10% SDS       50 µl 
APS        25 µl 
TEMED      7.5 µl 
 
 
2.8.2.2 Ponceau Red staining 
 
Ponceau S is a sodium salt of a diazo dye which is used to prepare a reversible stain for the 
detection of protein bands on nitrocellulose or PVDF membranes.  
 
 
2.8.2.3 Electrophoretic mobility shift assay (EMSA) 
 
An electrophoretic mobility shift assay (EMSA) is a generally used affinity electrophoresis 
technique to examine protein-DNA connections and to identify sequence-specific DNA-
binding proteins (such as transcription factors) in tissue/cell lysates. The proteins isolated 
from nuclear fractions bind to specific, radioactive labelled nuclear DNA sequences. Thereby 
the transfer of the protein-DNA complexes are more slowly than free linear DNA fragments 
within the non-denaturing polyacrylamide gel during electrophoresis (FRIED 1989; FRIED and 
CROTHERS 1981; GARNER and REVZIN 1981). After preparing the DNA oligonucleotide 
(described below) radioactive [γ-32P]-ATP was added and incubated for 30 minutes at 37ºC. 
During this time the DNA sample incorporated 32P by 5’ end labelling using [γ-32P]-ATP and 
a T4 polynucleotide kinase. Then, the counts of the radioactive probe were measured to 
investigate how much of the radioactive probe is needed for the assay. The master mix was 
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then prepared (described below), the proteins (4µg protein/sample) and the probe added. The 
master mix includes components that influences the strength and specificity of the 
protein:DNA interactions such as ionic strength and pH of the binding buffer, glycerol or 
carrier proteins (e.g. BSA), the absence of divalent cations (e.g. EDTA→Mg2+), the 
concentration of a competitor DNA (e.g. poly[dI·dC]; these repetitive fragments or polymers 
provide an excess of non-specific sites to adsorb proteins in lysates binding to any general 
DNA sequence), the temperature and the timespan of the binding reaction. The mix is 
incubated for 15 minutes at room temperature and afterwards incubated another 15 minutes on 
ice, at this step 1µl of the supershift antibody was added. The samples were subjected to the 
non-denaturing TBE-polyacrylamide gel and electrophoretic separation occurred at 100 V in 
0.5x TBE buffer for 3 hours. Subsequently, the gel was incubated for 10 minutes in fix-
solution at room temperature to denaturate the proteins in the gel. Afterwards, the gel was 
removed from the glass plate by using Whatman® paper, put into a gel dryer, masked with 
plastic wrap, and was dried for 1.5 hours using a vacuum pump. The dried gel was exposed to 
an X-ray film over night at -80ºC to document the results.  
     
 
 
Buffer    additives    volume final concentration 
Binding buffer (10x)  1 M Tris, pH 7.5  50 µl   100 mM 
5 M NaCl   100 µl           1M 
1 M DTT     25 µl     50 mM 
0.1 M EDTA     50 µl     10 mM 
100% Glycerol  200 µl         40% 
BSA (10mg/ml)     50µl    1mg/ml 
 
TBE running buffer (10x) 
(Tris-Borat-EDTA-buffer) Tris    108 g   892 mM 
1 litre     Borat      55 g   890 mM 
0.5 M EDTA (pH 8.0) 40 ml       2 mM 
→ dd H2O ad 1 liter  
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TE buffer    1 M Tris, pH 7.6  1.0 ml     10 mM 
(Tris-EDTA-buffer)  0.5 M EDTA   0.2 ml       1 mM 
→ dd H2O add 100 ml 
 
 
Buffer      additives    volume 
Protein inhibitor cocktail   1 M DTT         2 µl 
0.1 M Pefablock        5 µl 
Aprotinin (1 mg/ml)      20 µl 
dd H2O       73 µl 
 
Master-Mix      Binding buffer (10x)        2 µl 
(for 1 sample)     Protein inhibitor cocktail       2 µl 
Poly(dI·dC)         2 µl 
BSA (1mg/ml)        1 µl 
 
Fix-solution (EMSA gel)   Methanol            200 ml 
Acetic acid (conc.)           100 ml 
dd H2O            700 ml 
 
 
Buffer/reaction mix    additives    volume 
Non-denaturating separation gel  TBE buffer (10x)             6.0 ml 
Polyacrylamide    9.9 ml 
10% APS     1.2 ml 
ddH2O             42.75 ml 
1 M DTT       12 µl 
TEMED       36 µl 
 
NF-κB Oligo     DNA-Primer 1 (sense)     18 µl 
DNA-Primer 2 (antisense)     18 µl 
NEB buffer 2         4 µl 
→ NF-κB oligo was boiled in a waterbath for 3 minutes at 95°C and then slowly cooled down     
     at room temperature 
Materials and Methods 
32 
→ DNA concentration (1:5 diluted in ddH2O) was determined at 260 nm by using a   
     spectrophotometer 
→ the final concentration was adjusted to 50 ng/µl 
 
 
Loading buffer   100% Ficoll         2 ml 
→ ddH2O ad 10 ml 
→ one Eppendorf tube was filled with 100µl Ficoll  
     (20%) and Bromphenolblue ad libitum  
 
Radioactive NF-κB probe  NF-κB oligo (50ng/µl)       2.3 µl 
T4-Kinase buffer (10x)       2.0 µl 
T4 polynucleotide kinase       1.0 µl 
32P-ATP         4.0 µl 
→ is incubated for 30 minutes at 37°C 
→ 30 µl TE buffer was added 
→ the labeled oligonucleotide was centrifuged, using a 
     ProbeQuant™ G-50 Micro Column Nick- spin    
     column for 1 minute at 3000 rpm in order to remove  
     non-bound [32P]-γ-ATP 
 
 
2.8.3 Isolation and analysis of genomic DNA 
2.8.3.1 Polymerase chain rection (PCR) 
 
The polymerase chain reaction (PCR) is a generally used technique to amplify a single or few 
copies of a DNA sample. During this process cycles of repeated heating and cooling of the 
reaction-mix occurred to induce melting and replication of the DNA. Thus, specific primers 
and a heat-stable DNA polymerase were used to permit selective and repeated amplification 
of the DNA sample. The processed DNA itself is used as a template for replication, initiating 
a chain reaction in which the DNA template is exponentially amplified (BARTLETT and 
STIRLING 2003; SAIKI et al. 1985). The tail biopsies of TAK1LPC-KO and NEMOLPC-KO mice or 
mice transgenic for Cre recombinase were dissolved in tailing buffer (DirectPCR Lysis 
reagent) containing freshly prepared Proteinase K (0.2-0.3 mg/ml) and were incubated at 
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56°C and 750 rpm using a thermomixer until complete lysis was achieved (3-16 hours). Then, 
the tails were heated at 85°C for 45 minutes and 750 rpm. Subsequently, the extracted DNA 
was centrifuged full speed for 10 seconds and transferred into a new Eppendorf tube to 
remove interfering hairs and particles. The DNA was genotyped by PCR-protocols described 
below. Afterwards 2µl of loading buffer was added to the samples and the PCR products were 
applied to a TAE-ethidiumbromide-agarose gel and electrophoretic separation occurred at 120 
V in TAE buffer for 30 minutes. Finally, the bands were visualized by using a UV 
transilluminator (GelDoc 2000). Photos were taken for documenting the results. 
 
 
PCR protocol for Cre  
 
Primer # 1:  5’-GTC CAA TTT ACT GAC CGT ACA C-3’ (100 pmol) 
Primer # 2:  5’-CTG TCA CTT GGT CGT GGC AGC-3’     (100 pmol) 
→ primers were diluted 1:10 in ddH2O 
 
Master-mix (1x) 
Buffer (10x)    3 µl 
2 mM dNTPs     3 µl 
Primer Mix (each 3µM)  3 µl 
25 mM MgCl2            1.8 µl 
DNA     2 µl 
Taq (5U/µl)           0.5 µl 
ddH2O          16.7 µl 
 
PCR-programme 
94°C      3 minutes 
94°C    30 seconds 
61°C     30 seconds 
72°C    30 seconds 
30 cycles 
72°C      3 minutes 
→ used 1% TAE-ethidiumbromide-agarose-gel 
→ expected band for Cre: 350 bp  
Materials and Methods 
34 
PCR protocol for TAK 1 
 
Primer # 1:  5’-GGC TTT CAT TGT GGA GGT AAG CTG AGA-3’ (100 pmol) 
Primer # 2:  5’-GGA ACC CGT GGA TAA GTG CAC TTG AAT-3’ (100 pmol) 
→ primers were diluted 1:10 in ddH2O 
 
Master mix (1x) 
Buffer (10x)       3 µl 
2 mM dNTPs       3 µl 
10 µM Primer       3 µl 
25 mM MgCl2    3.6 µl (f.c. 3 mM) 
DNA         2 µl 
Taq (5U/µl)    0.2 µl 
ddH2O              15.2 µl 
 
 
PCR-programme  
94°C         2 minutes 
94°C       30 seconds 
67°C       30 seconds 
72°C         1 minute 
    34 cycles 
72°C       10 minutes 
  4°C    HOLD 
→ used 2% TAE-ethidiumbromide-agarose-gel 
→ expected band for WT: 280 bp, floxed site: 320 bp 
 
 
PCR protocol for NEMO 
 
Primer # 1:  5’-GCC TTG GTG CTC CCT AAC TCT CT-3’        (100 pmol) 
Primer # 2:  5’-TAT GTT TCA CAT CAC ATC GTT ATC C-3’  (100 pmol) 
→ primers were diluted 1:10 in ddH2O 
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Master mix (1x) 
Buffer (Clontech)      2 µl 
2 mM dNTPs    1.6 µl 
Primer # 1 (1:10)   1.0 µl 
Primer # 2 (1:10)   1.0 µl 
DNA     2.0 µl 
AdvantageTaq (Clontech; 5U/µl) 0.4 µl 
ddH2O      13 µl 
 
PCR-Programme 
95°C        15 minutes 
98°C        15 seconds 
55°C        30 seconds 
72°C        40 seconds 
    35 cycles 
72°C          5 minutes 
  4°C          1 minute 
→ used 2% TAE-ethidiumbromide-agarose-gel 
→ expected band for WT: 450 bp, floxed site: 550 bp 
 
TAE-ethidiumbromide-agarose gel 
TAE buffer    200 ml 
Agarose    2-4 g (1-2%) 
Ethidiumbromide   10 µl 
 
Loading buffer 
100% Ficoll  
→ 1.5 ml Ficoll (100%) 
→ ddH2O ad 10 ml 
→ Orange G ad libitum 
 
Stock solution Proteinase K 
Proteinase K (10 mg/ml) was dissolved in 50 mM Tris buffer (pH 8.0)  
 
Materials and Methods 
36 
2.8.3.2 Quantitative real-time PCR (qRT-PCR) 
2.8.3.2.1 Isolation of RNA from liver tissue 
 
A piece of deep-frozen liver tissue were transferred into a fermentation tube and homogenized 
in 1 ml Trizol (Invitrogen). The lysate were transferred into an Eppendorf tube and 
centrifuged for 15 minutes at 12000 rcf and 4°C. The supernatant was filled into a fresh 
Eppendorf tube (contains the RNA) and was incubated for 5 minutes at room temperature to 
initiate the dissociation of the nucleo-protein-complexes. Then, 200µl of chloroform was 
added to each sample and mixed thoroughly for 15 seconds and incubated for 3 minutes. The 
tubes were centrifuged again at 12000 rcf and 4°C for 15 minutes thereby three phases were 
formed. The liquid upper phase included the disassociated RNA, whereas the interphase and 
the lower phase contained impurities of DNA and protein. The upper phase (approx. 600µl) 
was transferred into a fresh Eppendorf tube without touching the interphase, 1 volume of 
ethanol (70%) was added and mixed gently. The total RNA was purified by using an RNeasy 
Mini kit according to the manufacturer’s protocol. The isolated RNA was shock frosted and 
stored at -80°. 
 
 
2.8.3.2.2 Determination of RNA concentration 
 
The extracted RNA was diluted 1:50 in DEPC treated water and the extinction was measured 
spectroscopically at 260 nm. Calculation of RNA concentration based on the formula: 
                                        1OD260 = 40µg RNA/ml. 
The purity of RNA is examined by the ratio of E260/E280; the expected ratio is 1.8 to 2.1. 
 
 
2.8.3.2.3. Reverse Transcription (RT-PCR) 
 
Reverse transcription is a process in which single-stranded RNA is reverse transcribed into 
complementary DNA (cDNA). Total RNA (3µg) was used to synthesize cDNA using the 
SuperScript III First-Strand Synthesis System according to the manufacturer’s protocol. 
This procedure was performed by using total cellular RNA, a reverse transcriptase enzyme, 
random primers, dNTPs and an RNase inhibitor. For a real time reaction, 3µg of RNA was 
first incubated at 65°C for 5 minutes to denature secondary structures of RNA and was then 
quickly cooled on ice. Afterwards, 10µl of the cDNA-synthesis-master mix was applicated to 
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each sample. The real time reaction mix was then incubated for 10 minutes at 25°C and 50 
minutes at 50°C. The enzyme was inactivated during incubation at 85°C for 5 minutes. After 
cooling, 1 µl RNase H was added to cleave RNA/DNA duplexes to produce single strand 
DNA. The reaction mix was incubated for 20 minutes at 37°C. Finally, the received c-DNA 
was diluted 1:10 in DEPC treated water and stored at -20°C. For real-time PCR 2µl of each 
cDNA sample was added into a total volume of 25µl containing SYBR Green Reagent and 
specific primers and enzymes. The c-DNA synthesis was generated by using a qPCR machine 
(Applied Biosystems 7300 Sequence Detection System). All real-time PCR reactions were 
performed in duplicates. Analysis of the data was performed by the SDS 2.3 and RQ manager 
1.2 software. All values were normalized to the mRNA level of β-actin. 
 
cDNA-synthesis-mastermix (1x): 
RT buffer (10x)   2µl 
25 mM MgCl2    4µl 
0.1 M DTT    2µl 
RNase OUT (40U/µl)   1µl 
SuperScript III RT (200U/µl) 1µl 
 
 
2.8.3.2.4 Real time PCR (qRT-PCR) 
 
Quantitative real time polymerase chain reaction (Q-PCR/qPCR/qRT-PCR) is a method 
similar to the PCR technique to quantify the expression of a particular gene.. The principal 
feature of this method is that amplified DNA will be detected in real time, which is. contrary 
to standard PCR, where the product of the reaction is detected at its end. There are two 
possibilities to detect real-time PCR products : a) the use of non-specific fluorescent dyes 
which intercalate within double-stranded DNA, and b) labelling with a fluorescent reporter 
which allows detection only after hybridization of the probe with its complementary DNA 
target (e.g. SYBR green) (WARDS and COURTS 1977). Therefore, an increasing amount of 
DNA product during PCR causes an increase in fluorescence intensity and is measured at 
each cycle, thereby allowing DNA concentrations to be quantified. The dye SYBR Green 
binds in the minor groove of double stranded DNA leading to an enhanced intensity of 
fluorescent emission.  
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To analyze gene expression messenger RNA (mRNA) will be quantified. Therefore, reverse 
transcriptase is used to convert mRNA into complementary DNA (cDNA), which finally gets 
amplified and analyzed by PCR. There are different methods to quantify alterations in mRNA 
levels: absolute and relative quantification. Absolute quantification means calculation of the 
amount of DNA molecules performed by calibration with a standard curve. 
In the present studies an approximation method was used providing relative quantification. 
The ∆∆Ct method was one of the first methods to be used to calculate real time PCR results 
(Applied Biosystems; User Bulletin #2: Relative Quantitation of Gene Expression (PN 
4303859). This comparative method involves comparing the Ct values (cycle threshold), the 
fractional cycle number at which the fluorescence passes the fixed threshold. The Ct values of 
the samples of are compared with a control or calibrator such as a non-treated sample or RNA 
from normal tissue. The Ct values of both the calibrator and the samples of interest are 
normalized to an appropriate endogenous housekeeping gene. 
[delta][delta]Ct = [delta]Ct, sample - [delta]Ct, reference 
Here, [delta]CT, sample is the Ct value for any sample normalized to the endogenous 
housekeeping gene and [delta]Ct, reference is the Ct value for the calibrator also normalized 
to the endogenous housekeeping gene. 
 
 
Master Mix (1x):  12.5 µl  SYBR® GreenER qPCR SuperMix 
  9.5 µl  DEPC-H20 
  0.5 µl  sense primer (10 pM) 
  0.5 µl  antisense primer(10 pM) 
  2.0 µl  cDNA 
25.0 µl  final volume 
 
The following PCR program was used for all real-time primer pairs: 
 
Procedure    Temperature   Duration   Step  Cycle 
1. Activation    50°C     2 min 
2. Denaturation   95°C    10 min 
3. Denaturation   95°C    15 sec   
4. Annealing    60°C    30sec   
5. Elongation   60°C   30 sec      3      40 
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6. Consercation    4°C   ∞ 
→ the specificity of PCR products was confirmed by melting curves 
 
 
2.9 Analysis and preparation of Immunohistochemical and histological stained liver  
      tissue 
2.9.1 Immunohistochemistry 
 
Immunohistochemistry is commonly used in the research field to visualize distribution and 
localization of biomarkers and the expression pattern of particular proteins in different parts 
of biological tissues.  
Imaging of antibody-antigen interaction can be realized in different ways. One of the most 
common techniques that, an antibody is conjugated to an enzyme, such as peroxidase, that 
catalyses a colour-producing reaction (e.g. immunoperoxidase staining). Otherwise the 
antibody can also be tagged to a fluorophore (immunofluorescence), such as fluorescein, 
rhodamine, or Alexa Fluor (RAMOS-VARA 2005). 
Frozen murine liver sections (7µm) were fixed in paraformaldeyde (4% buffered in PBS) for 
20-30 minutes at room-temperature, washed three times in PBS for 5 minutes and were 
incubated for 1 hour at room temperature in blocking solution (10% BSA in PBS) to prevent 
unspecific binding of the primary antibody. Then, the blocking solution was removed and 
primary antibody was added in blocking solution at a dilution according to the manufacture’s 
recommendation (1:50-1:500). Slides were incubated over night in a wet chamber at 4°C. 
Afterwards, the slides were washed three times in PBS for 5 minutes at room temperature and 
the secondary antibody were added and incubated 1 hour at room temperature in a dark wet 
chamber to avoid fading of the fluorochrome. Finally, the slides were washed three times in 
PBS for 5 minutes to remove unbound secondary antibody. Nuclei were visualized by using 
mounting medium containing DAPI (Vectashield; Vector Laboratories). The slides were 
covered with cover slips and specimens were examined under a fluorescence microscope by 
using appropriate excitation wavelengths depending on the fluorochrome used. 
 
 
2.9.1.1 Terminal deoxynucleotidyl transferase dUTP-mediated nick end labeling (TUNEL) 
 
Apoptosis or programmed cell death is characterized by several morphological changes, such 
as cell shrinkage, nuclear condensation, membrane blebbing and fragmentation into 
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membrane bound apoptotic bodies. During apoptosis DNA is cleaved by nucleases in a 
characteristic pattern with free 3’-OH ends. This allows the detection of apoptotic cells by 
connecting fluorescence-labeled dUTP to the free 3’-OH ends using the enzyme terminal 
deoxynucleotidyl transferase (TdT) in a procedure termed terminal deoxynucleotidyl 
transferase dUTP-mediated nick end labeling (TUNEL) (DESCHESNES et al. 2001; ELMORE 
2007; GAVRIELI et al. 1992). 
The TUNEL test was performed by using the DeadEnd™ Fluorometric TUNEL kit from 
Promega according to the instruction manual. Nuclei were visualized by using mounting 
medium containing DAPI (Vectashield; Vector Laboratories).  
 
 
2.9.1.2 5-Bromo-2’-deoxyuridine (BrdU) staining of frozen sections of liver tissue 
 
Bromodeoxyuridine (5-bromo-2’-deoxyuridine, BrdU) is a synthetic nucleoside and is 
analogue to the nucleoside thymidine. BrdU is generally used to detect proliferating cells in 
living tissues. During the S phase of replicating cells BrdU incorporates into the newly 
synthesized DNA by substitution of thymidine. The incorporated BrdU can be visualized by 
performing immunohistochamical staining with a specific antibody against BrdU 
(CHOUDHARY et al. 2010). 
To measure DNA replication, 30µg per g mouse body-weight of 5-Bromo-2’-deoxyuridine 
(BrdU, Amersham) were injected i.p. every 8 hours for 2 days. The mice were sacrificed 2 
hours after the last injection. Cryosections (7µm) were prepared, fixed in ice-cold 
Aceton/Methanol (1:1) for 10 minutes. Afterwards the slights were washed three times in 
TBS-Tween (0.05%) and incubated in ethanol (70%) for 30 minutes at room temperature. 
After the incubation, the slides were dried for another 30 minutes meanwhile two formamide 
solutions were prepared. Two separate beakers were filled with 95 ml of formamide and kept 
at 70°C in the water bath; 5 ml of tri-sodiumcitrate were added in one of the beakers filled 
with formamide. 5 ml of 1N NaOH were added into the second beaker and mixed thoroughly 
for 8 minutes. Then, this solution was filled into a fresh cuvette and the slides were incubated 
for exactly 30 seconds at 70°C in the water bath. The slides were washed again in TBS-
Tween (0.05%) for 5 minutes at 70°C. Afterwards the slides were incubated in formamide-
sodiumcitrate solution for 15 minutes at 70°C in the water bath. Then, the slides were washed 
twice in ice-cold TBS-Tween (0.05%), each washed for 5 minutes. The tissue was fixed with 
3% formaldehyde for 30 minutes at room temperature. Subsequently, the slides were washed 
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three times for 5 minutes and immersed in glutaraledehyde (1%) for 10 minutes at room 
temperature. After washing with TBS-Tween (0.05%), twice for 5 minutes, the liver tissue 
sections were blocked 30 minutes with goat serum (10% in PBS) at room temperature, 
followed by incubation with anti-Bromodeoxyuridine [dilution 1:200 in PBS (+0.25% fish 
gelantine)] for 2 hours at room temperature or over night at 4°C. Afterwards the slides were 
washed three times for 5 minutes with TBS-Tween (0.05%) and incubated with AlexaFluor 
594 (dilution 1:500 in PBS). Nuclei were visualized by using mounting medium containing 
DAPI (Vectashield; Vector Laboratories).  
 
 
Buffer/Fix solutions    additives   volume 
TBS-Tween (10x), 1 litre   Tris    24.2 g 
NaCl     80.0 g 
→ pH 7.6 (determination with HCl) 
→ 1 ml Tween-20 added to 1liter of TBS-buffer  
     (1x) 
0.15 M Tri-sodiumcitrate, 200 ml      7.7 g 
 
3% Formaldehyde   3 ml of 37% Formaledhyde in 108 ml PBS 
 
1% Glutaraldehyde   0.8 ml of 25% Glutaraledhyde in108 ml PBS 
 
 
2.9.1.3 Nucleic Staining Estimation (Ki67) 
 
To determine if a detected nucleus is positively stained for an antibody, its color histogram is 
compared to two predefined prototypes for stained and non-stained nuclei. These prototypes 
are learned by averaging the color histograms of 50 labeled nuclei per group. The nucleus is 
then assigned to the nearest prototype in Euclidian distance and hence considered stained or 
not-stained. 
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2.9.1.4 Image Acquisition 
 
Murine hepatic tissue from independent experiments was formalin fixed and paraffin 
embedded. Sections were cut at a thickness of 2µm, stained with the Ki67 antigen. Slices 
from the murine tissue block were scanned on a Nanozoomer C9600 virtual slide light 
microscope scanner from HAMAMATSU. The magnification of 40× resulted in a per pixel 
resolution of 0.23µm. Finally, 10 patches of size 2000 × 2000 pixel were randomly sampled 
from whole tissue slides of each mouse. 
 
 
2.9.1.5 Tissue Classification and Tissue Staining Estimation (Necrosis, bile duct density) 
 
Tissue classification is used to find areas of necrosis or areas with positive staining response 
in cytoplasm. Again, a RDF classifier was learned for this task, but unlike nuclei detection, 
the feature basis for the classifier consisted of 10 features per color channel comprising the 
average intensity and an eight bin histogram of the surrounding patch in addition to the single 
pixel intensity. The final readout was the number of pixels in the probability map indicating a 
classifier confidence of more than 80%. This represents area of necrosis response 
respectively. Number of bile ducts, positively stained for cytokeratin, was counted manually 
(three independent measurements per liver).  
 
 
2.9.2 Histological staining methods 
2.9.2.1 Hematoxylin-eosin staining 
 
Hematoxylin and eosin stain is one of the most important standard staining methods used in 
histology. It gives a structural overview of the tissue, allowing differentiation of the structures 
being classified as normal, inflamed or pathological. First, the nuclei are stained with a 
hematoxylin solution, appearing blue or dark violet. During the second step the tissue is 
counterstained with a xanthene dye, e.g. eosin Y, eosin B or erythrosin B. In this process 
cytoplasm, collagen, keratin and erythrocytes stained red (LLEWELLYN 2009). 
The liver sections were fixed in paraformaldehyde (4%) and were given to the laboratory 
technicians of the Institute of Pathology, University Hospital Aachen. The liver tissues were 
embedded in paraffin and sections (2µm) were stained with H/E according to standard 
procedures.  
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2.9.2.2 Sirius red staining 
 
Sirius red staining is a standard procedure for staining different types of collagen, e.g. I, III 
and IV (WALSH et al. 1992). The liver sections were fixed in Paraformaledhyde (4%) and 
were given to the laboratory technicians of the Institute of Pathology, University hospital 
Aachen. The liver tissues were embedded in paraffin and sections (2µm) were stained with 
Sirius red according to standard procedures and were examined by polarised light microscopy. 
 
 
2.10 Hydroxyproline assay 
 
Hydroxyproline differs from proline by the presence of a hydroxyl (OH) group attached to the 
C (γ) atom. Hydroxyproline is generated as a post-translational modification by hydroxylation 
of the amino acid proline catalyzed by the enzyme prolyl-hydroxylase. This reaction takes 
place in the lumen of the endoplasmic reticulum. Hydroxyproline is the main component of 
the protein collagen. Hydroxyproline and proline are most important for collagen stability 
(NELSON and COX 2005) by mediating the sharp twisting of the collagen helix (BRINCKMANN 
et al. 2005). Hydroxyproline is found in only few proteins in contrast to collagen. The only 
other mammalian protein that includes hydroxyproline is elastin. Thus, the content of 
hydroxyproline functions as an indicator to verify the amount of collagen and/or gelatin 
(WARDS and COURTS 1977).  
Pieces of deep frozen liver tissue (30-50 mg) were homogenated in 1 ml of 6N HCl and 
incubated for 16 hours at 110°C. Then, the homogenate was filtrated by a syringe filter 
(Minisart SRP4; Sartorius); the supernatant has to be clear with a yellow appearance. Samples 
of the supernatant equivalent to 0.75 mg of liver tissue (~15µl) were diluted in 15µl Methanol 
and evaporated for 45 minutes using a vacuum centrifuge meanwhile a hydroxyproline 
standard curve was prepared. The lyophilisate was dissolved in 50µl Isopropylalcohol (50%) 
and mixed thoroughly. Then, 100µl Chloramin-T solution was added to 50µl of the sample 
and hydroxyproline standard, mixed and incubated for 10 minutes at room temperature 
(oxidization step) Afterwards, 100µl of freshly prepared Ehrlich’s reagent were added and 
incubated for 45 minutes at 50°C. The samples were measured at 570nm using a 
spectrophotometer. The proline concentration of each sample was calculated in Excel on the 
basis of the hydroxyproline standard curve. Hydroxyproline contents of individual liver 
tissues were expressed as µg hydroxyproline/g liver weight. 
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Buffer/solution    additives    volume 
Buffer A     NaOH     3.4 g 
      Citric acid*H2O   3.4 g 
      Sodium acetate*3H2O  12 g 
      → determine to pH 6.0 
      → ad 100 ml ddH2O 
 
Buffer B     Isopropyl alcohol   60 ml 
      ddH2O     33 ml 
      Buffer A    39 ml 
 
0.6% Chloramin-T-Solution   Chloramine-T            300 mg 
      Buffer B    50 ml 
 
 
 
Ehrlich’s reagent solution   Ehrlich’s reagent       3 g 
      (4-Dimethylamino-benzaldehyde) 
      Isopropyl alcohol   26 ml 
      Perchloric acid (50%)    8 ml 
 
 
2.11 Laser dissection microscopy 
 
Laser dissection microscopy is a technique to cut out individual cells or small cell populations 
from histological sections, cytosmears, cytospins and living cultures for genomic and mRNA 
or protein expression analysis. The microscopes used in laser dissection microscopy are 
upright or inverted compound microscopes and tissues can be micro-dissected in all forms of 
bright field and dark field illumination, fluorescence and, confocal microscopy. (BALL et al. 
2002; LEE et al. 2003; SCHUTZE et al. 1997; STICH et al. 2003). 
Pieces of freshly dissected liver tissue from WT and TAK1LPC-KO mice were embedded in 
Tissue Tek and sections (5µm) were stained for oval cells and cholangiocytes using an anti-
A6 antibody (provided by V. Factor). Laser microdissection was performed on A6-positive 
oval cells, bile duct epithelia and A6-negative hepatocytes by using a Palm MicroBeam 
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Microdissection Microscope (Zeiss) as described (BURBACH et al. 2004) with slight 
modifications. Fast immunochemistry of serial liver sections from WT and TAK1LPC-KO mice 
was performed. RNA was isolated with the RNeasy Micro Plus Kit (Qiagen) according to the 
manufacturer’s recommendations. Reverse transcription and quantitative real-time PCR were 
performed using Applied Biosystems reagents as described recently (BURBACH et al. 2004). 
 
 
2.12 Array-based Comparative Genomic Hybridization (aCGH) 
 
The molecular-cytogenetic method of comparative genomic hybridization (CGH) is used to 
analyze copy number alterations (gains/losses) in the DNA content of various cell types. It is, 
most frequently used for examination of modified DNA in tumour cells.  
Thereby, DNA from a test sample and normal reference sample are labelled, using different 
fluorophores (generally FITC and Texas red), and hybridized to several thousand probes. 
These probes are derived from well known genes and non-coding regions of the genome, 
printed on a glass slide. Subsequently, the ratio of the fluorescence intensity of the DNA 
sample to that of the reference DNA is then calculated to detect the copy number changes for 
a specific location in the chromosome. 
This method detects only unbalanced chromosomal changes, whereas structural chromosome 
aberrations such as balanced reciprocal translocations or inversions cannot be detected as they 
do not change the copy number. 
Agilent oligonucleotide array based CGH for Genomic DNA analysis for formalin-fixed, 
paraffin-embedded (FFPE) samples (Mouse Genome CGH Microarray 4x44K) was 
performed according to the protocol provided by Agilent Technologies. Chromosomal copy 
number aberration in HCC samples of TAK1LPCKO livers in relation to WT samples were 
investigated using aCGH (Agilent DNA Analytics 4.0 CGH Module User Guide). Log2-ratios 
of signal intensity values of WT (Cy5) versus signal intensity values of HCC (Cy3) samples 
were computed with Agilent Feature Extraction software Version 9.5.3.1. Log2 ratios were 
imported into the DNA Analytics Software 4.0.76 (Agilent Technologies, USA). Saturated 
and non-uniform data points were filtered out. Values of probes that occurred several times 
within one chip were combined and averaged. The aCGH data were then normalized in a 
linear way using DNA Analytics centralization method. Aberrations were detected using the 
Aberration Detection Method Nr.1 (ADM-1) as implemented in the DNA Analytics software 
(Agilent DNA Analytics 4.0 CGH Module User Guide, Agilent Technologies, Inc. 2008) with 
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standard settings. Those aberrations that were not covered by more than two probes were 
filtered out. Single log2 ratio intensities, moving average of these ratios and aberration 
detection results were graphically displayed in the genome browser of the DNA Analytics 
software.  
In addition, the aCGH data were analyzed using Partek® Genomics Suite software, version 
6.4 (Copyright © 2008, Partek Inc., St. Louis, USA). After importing the array data into 
Partek, it was transformed into adjusted copy number data as described in the manual. 
Amplifications and deletions were detected by applying the genomic segmentation workflow. 
The optimal segmentation and region report parameters were found by following an iterative 
procedure (Partek support, personal communication) and finally set as follows: minimum 
number of genomic markers = 10, segmentation P-value = 0.001, signal to noise ratio = 0.2, 
expected range = 0.3, region p-value = 0.01. On the resulting segmentation data the workflow 
was applied to find regions in multiple samples, reporting all regions that were significant in 
at least two samples. The related cytobands are indicated for each chromosome as horizontal 
bars. Annotations for these regions are available under supplemental online material. The 
cytoband information was obtained from the UCSC genome bioinformatics database 
(http://genome.ucsc.edu). 
Statistical significance of amplification and deletion patterns in aCGH for monoclonal 
tumours was calculated by applying a permutation test. The samples were compared pair-wise 
as follows using an in-house written program. First, the sequence overlap (o) of 
amplifications/deletions was calculated for the two samples. Then, the 
amplifications/deletions of one sample were kept but randomly distributed on the other 
sample and the new overlap (ri) calculated. This step was repeated n = 1 x 107 times and r = 
sum (ri > o) computed. Finally, the p-value for the pair-wise comparison was estimated as p = 
r/n. Transcriptional levels of oncogenes an tumor-suppressor genes were analysed by qRT-
PCR analysis on RNA extracts from HCC micro-dissected from TAK1LPC-KO livers and were 
compared with whole-liver RNA extracts from age-matched WT-controls.  
 
 
2.13 Bonferroni-Correction 
 
The Bonferroni correction is a statistical formula used to solve the problem of multiple 
comparisons.The correction is based on the theory that if an experimenter is testing n 
dependent or independent hypotheses on a set of data, then one way of preserving the 
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familywise error rate is to test each individual hypothesis at a statistical significance level of 
1/n times what it would be if only one hypothesis were tested. If the significance level for the 
whole family of tests should be (at most) α, then the Bonferroni correction would be to test 
each of the individual tests at a significance level of α/n.  
 
 
2.14 Heat map 
 
A heat map is a graphical model to show data in a two-dimensional map which is represented 
as colours.  
Larger values were symbolized by dark squares (e.g. green) and smaller values by lighter 
squares (e.g. red).  
Heat maps are generally used in molecular biology to show the expression level of many 
genes compared to a number of analogous samples (e.g. cells in different states, samples from 
different patients) which are generated from DNA microarrays. 
Different computer programs are available to visualize the obtained data as a heat map.  
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3. Results 
3.1 Spontaneous development of hepatocyte injury, hepatitis, cholastasis, and 
spontaneous death in TAK1LPC-KO mice 
 
As outlined in the introduction, TAK1 is a key regulator of signal transduction cascades 
leading to the activation of the transcription factors nuclear factor-kappa B (NF-κB) and 
activator protein-1 (AP-1). TAK1 is located upstream of the IKK-complex and 
phosphorylates the catalytic subunit IKK-β, leading to the activation and nuclear localisation 
of NF-κB (ADHIKARI et al. 2007). The study from Luedde and colleagues in 2007 showed 
that deletion of the regulatory subunit of the IKK-complex, NEMO, in liver parenchymal cells 
(LPC) causes spontaneous development of hepatitis and hepatocellularcarcinoma (HCC). To 
clarify the specific function of TAK1 in liver we compared our results with them of the 
NEMOLPC-KO phenotype.  
Therefore, we generated a specific deletion of the TAK1 gene (Map3k7) in LPC by 
intercrossing TAK1 floxed mice (TAK1Fl/Fl) with transgenic mice expressing the Cre-
recombinase under the control of the mouse albumin regulatory elements and as well as the α-
fetoprotein enhancers (Alfp-Cre transgene) (KELLENDONK et al. 2000). 
At first, the efficiency of Tak1 and Nemo deletion in liver parenchymal cells was 
demonstrated by Western blot analysis of whole liver protein lysates which showed very 
efficient ablation of the respective proteins (Figure 5A). 
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Figure 5. Spontaneous development of liver injury and Cholestasis in TAK1LPC-KO mice. (A) Western blot analysis of 
whole liver protein extracts from 6 week old TAK1LPC-KO, NEMOLPC-KO, and littermate mice (WT) using antibodies against 
TAK1, NEMO, and GAPDH as loading control.. (B) Representative pictures of 6 week old male WT (left panel), TAK1LPC-
KO
 (middle panel), and NEMOLPC-KO livers (right panel). Small nodules were noticed in the livers of TAK1LPC-KO mice (black 
arrows). (C) Serum level analysis of alanine aminotransferase (ALT) and aspartate aminotransferase (AST), total and direct 
bilirubin, alkaline phosphatase (AP), and glutamate dehydrogenase (GLDH) in 6 week old male mice. Results are shown as 
mean, error bars indicate standard error of the mean. *p< 0.05; **p< 0.01; ***p< 0.001; n= 4 each genotype. 
 
 
At 6 weeks of age, TAK1LPC-KO mice showed strong modifications of the liver architecture, 
including several macroscopically visible nodules. Notably, these livers showed a mild icteric 
appearance when compared to wild-type (WT) and NEMOLPC-KO mice (Figure 5B). These 
findings were strengthened by significantly elevated blood serum aminotransferase [AST 
(2180 ± 306 U/l) and ALT (1518 ± 301 U/l)] and bilirubin levels (9 ± 0.5 mg/dl) in TAK1LPC-
KO
 mice (Figure 8C). Furthermore, significantly increased levels of alkaline phosphatase (AP) 
(668 ±153 U/l) and glutamate dehydrogenase (GLDH) (1652 ± 414 U/l) gave indication for 
the development of intrahepatic cholestasis whereas WT and NEMOLPC-KO mice showed 
decreased levels of bilirubin [WT (0.1 ± 0 mg/dl), NEMO (0.2 ± 0 mg/dl)] or cholestatic 
enzymes and displayed less elevated levels of ALT [WT (28 ± 8 U/l), NEMO (800 ± 133 
U/l)] and AST [WT (108 ± 16 U/l), NEMO (418 ± 55 U/l)] (Figure 5C).  
These findings indicated that deletion of Tak1 in liver parenchymal cells of 6 week old 
TAK1LPC-KO mice leads to the development of hepatitis and cholangitis accompanied by an 
initiating jaundice. Moreover, older mice (14 to 20 week old) showed progressive 
development of jaundice, which was visibly apparent by a yellowish appearance of the skin 
and paws (Figure 6A). The macroscopic pictures of these livers revealed a progressive growth 
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of the nodules and the development of tumours accompanied by a strong icteric appearance 
(Figure 6A and B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Further development of hepatocyte damage and severe jaundice. (A) Representative pictures from 20 week old 
TAK1LPC-KO mice demonstrating the progression of severe jaundice. (B) Representative macroscopic pictures of livers from 
20 week old male WT (left panel), TAK1LPC-KO (middle panel) and NEMOLPC-KO mice (right panel). Livers of TAK1LPC-KO 
animals showed several nodules variable in growth and size accompanied with strong icteric appearance. (C) Analysis of 
serum ALT, AST and total bilirubin levels in 20 week old male WT, TAK1LPC-KO, and NEMOLPC-KO mice. Results are shown 
as mean, error bars indicate SEM. **p< 0.01; ***p< 0.001; n=4 each genotype. 
 
 
Analysis of the blood serum from the 14 to 20 week old TAK1LPC-KO mice revealed reduced 
levels of ALT (338 ± 63 U/l) and AST (668 ± 91 U/l), compared to 6 week old animals [AST 
(2180 ± 306 U/l) and ALT (1518 ± 301 U/l)]. Moreover, age-matched NEMOLPC-KO mice 
showed similar ALT (304 ± 69 U/l) levels when compared with TAK1LPC-KO mice. The icteric 
appearance of the liver correlated with the elevated serum bilirubin levels observed in 
TAK1LPC-KO mice at both 6 weeks and 20 weeks of age (Figure 6C). Another important 
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finding was the spontaneous death of all TAK1LPCKO mice between 14 and 36 weeks of age 
(n=9), whereas no spontaneous deaths were detected in WT (n=15) or NEMOLPC-KO (n=15) 
within a period of 60 weeks (Figure 7). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Spontaneous death of TAK1LPC-KO mice. Kaplan-Meier curve showing spontaneous death of TAK1LPC-KO mice 
between 16-36 weeks of age. ***p< 0.001. WT n=15, NEMOLPC-KO n=15, and TAK1LPC-KO n=9. 
 
 
In summary, TAK1 ablation in liver parenchymal cells causes the development of severe 
hepatitis and cholangitis in 6 to 8 week old TAK1LPC-KO mice. Moreover, this genotype leads 
to an enhanced tumour development accompanied by a strongly elevated jaundice which 
causes increased lethality in TAK1LPC-KO mice.  
 
 
 
3.2 TAK1 ablation in liver parenchymal cells causes spontaneous development of liver 
fibrosis 
 
Several studies have shown that chronic hepatitis and cholestasis promote the progression of 
liver fibrosis (BATALLER and BRENNER 2005). Therefore, Sirius red staining was performed to 
evaluate the level of fibrosis in TAK1LPC-KO and NEMOLPC-KO liver. Histological analysis and 
quantification revealed periportal liver fibrosis and strong collagen deposition in TAK1LPC-KO 
and NEMOLPC-KO mice. These results indicate that deletion of either TAK1 or NEMO in LPC 
leads to massive fibrosis as demonstrated by Sirius red stained liver sections in 20 to 29 week 
old animals (Figure 8A and B). 
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Figure 8. Chronic hepatitis and cholestasis leads to liver fibrosis. (A) Representative liver sections of 6 (upper panels) and 
28 week old (lower panels) male WT, TAK1LPC-KO,and NEMOLPC-KO mice stained with Sirus red showing periportal fibrosis 
in younger mice and severe diffuse liver fibrosis in older TAK1LPC-KO mice (red: collagen decomposition). (B) Densitometric 
analysis of Sirius red stained collagen fibers from 6 and 20 to 29 week old male WT, TAK1LPC-KO, and NEMOLPC-KO mice 
(n= 6 each genotype at 6 weeks of age, n=4 each genotype at 20 to 29 weeks of age. Results shown as mean, and error bars 
indicate standard diviation (SD); *p< 0.05; **p< 0.01. (C) Hydroxproline assay quantifying the collagen content in liver. 
Results are shown as mean, error bars indicate SEM. *p< 0.05; **p< 0.01. 
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Next, the content of hydroxyproline in liver tissue from each genotype was examined. 
Hydroxyproline is a major component of collagen, playing an important role in collagen 
stability. This assay revealed significantly increased hydroxyproline content for TAK1LPC-KO 
(669 ± 111µg/g liver weight) and NEMOLPC-KO (377 ± 75µg/g liver weight) animals as 
compared to WT (98 ± 18µg/g liver weight) (Figure 8C). Furthermore, mRNA levels of key 
players of fibrogenesis such as MMP-1, MMP-9, Collagen Iα1, and all three isoforms of the 
potent fibrogenic cytokine TGF-β, were investigated, (BATALLER and BRENNER 2005; GONG 
et al. 1998; LINDQUIST et al. 2004). Analysis of the mRNA expression levels of these 
profibrotic mediators revealed strong upregulation (p<0.001 for Collagen Iα1, p< 0.01 for 
Mmp-1, and p< 0.01 for Mmp-9) in liver tissue from 6 week old TAK1LPC-KO mice as 
compared to WT (Figure 9A and B). Based on the finding of strongly elevated mRNA levels 
of TGF-β, the expression of p-SMAD2, p-SMAD3 and SMAD2/3 were examined by Western 
blot analysis and immunohistochemical staining (Figure 9C and D). SMAD2 and SMAD3 are 
important mediators of the TGF-β-signalling cascade, triggering the expression of collagen I 
(GUTIERREZ-RUIZ and GOMEZ-QUIROZ 2007). Western blot analysis revealed increased 
expression of p-SMAD2 and SMAD2/3 in livers from 6 week old TAK1LPCKO. In contrast to 
whole liver tissues from age-matched NEMOLPCKO mice showing similar levels as WT. This 
data suggests that the TFG-β signalling pathway plays a role in fibrogenesis in livers of 
TAK1LPC-KO and NEMOLPC-KO mice. 
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Figure 9. TAK1 deletion promotes fibrogenesis through TGF-β signalling cascade.  
(A) Quantitative RT-PCR analysis of Collagen Iα1 and Mmp-1 mRNA expression (n=4 each genotype) in livers of 6 week 
old male mice. All values were normalized to β-actin expression. Results are expressed as mean, error bars denote SEM. 
**p< 0.01. (B) Quantitative RT-PCR analysis of Tgf-β1, 2 and 3 mRNA expression in livers of male WT, NEMOLPC-KO, and 
TAK1LPC-KO mice (n=5 each genotype) at the age of 6 week. All values were normalized to β-actin expression. Results are 
expressed as mean, error bars denote SEM.*p< 0.05; **p< 0.01; ***p< 0.001. (C) Western blot analysis on whole liver 
protein extracts from 6 week old TAK1LPC-KO mice and WT mice at 6 weeks of age with antibodies against p-SMAD2, 
SMAD2/3; GAPDH was used as a loading control. (D) Immunohistochemical staining for the phosphorylated form of 
SMAD3 on liver paraffin sections from 6 week old male TAK1LPC-KO mice. Phosphorylated SMAD3 is detected mainly on 
hepatocytes (inset with higher magnification, arrowhead indicates a p-SMAD3+hepatocyte nucleus). 
 
 
 
3.3 Activation of the TGF-β pathway might promote epithelial to mesenchymal 
transition (EMT) in livers of TAK1LPC-KO mice  
 
Alongside the ‘classical’ functions of TGF-β in hepatic fibrosis (BATALLER and BRENNER 
2005), TGF-β may also promote epithelial-to-mesenchymal-transition (EMT), a recently 
identified mechanism in organ fibrosis (XU et al. 2009). Known markers of EMT such as 
Snail1 (p< 0.05) and Hey1 (p< 0.05) (SHEAHAN et al. 2008; ZAVADIL et al. 2004; ZEISBERG et 
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al. 2007) were investigated and found to be upregulated in livers of TAK1LPC-KO mice as 
compared to WT animals; whereas expression of cEBP/β, an epithelial marker for 
hepatocytes, was significantly downregulated (p< 0.05) in livers of these animals as shown by 
real-time PCR level (Figure 10A).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure10. Activation of TGF-β and features of epithelial to mesenchymal transition (EMT) in livers of 6 week old 
TAK1LPC-KO mice. (A) Quantitative RT-PCR analysis of the expression of markers of mesenchymal transition Hey1 and 
Snail1 and the epithelial marker c/epbβ in livers of WT and TAK1LPC-KO mice; *p< 0.05 (n=5). (B) Immunohistochemical 
staining of the tight junction associated proteins ZO-1 (green) and occludin (red). Blue represents nuclear DAPI staining. The 
WT cells showed a regular co-localization of ZO-1 and occluding (yellow) demarking cellular connections. In livers of 
TAK1LPC-KO mice, areas of co-localization (yellow) are rare with a more scattered distribution of ZO-1. The overall 
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architecture appears disturbed. Original magnification, x 200. (C) Quantitative RT-PCR analysis of the expression of markers 
of biliary EMT. *p< 0.05, **p< 0.01, ***p< 0.01 (n=5 per group for Fsp-1 and Vimentin; n=6 (WT)/ n=8 (TAK1LPC-KO) for 
Igf1r, Crim1, and Hhip). 
 
Additionally, hepatocytes in TAK1LPC-KO mice showed a disturbed cellular organization as 
demonstrated by co-staining with the cellular junction associated proteins occludin and ZO-1 
(Figure 10B), consistent with typical findings in tissues undergoing TGF-β-dependent EMT 
(XU et al. 2009).  
Based on recent data from man and rodents, TGF-β-dependent EMT appears to be of 
exceptional relevance in biliary fibrosis (OMENETTI et al. 2008; ROBERTSON et al. 2007). 
Different studies identified the genes Igf, Crim1, S100A4 (Fsp-1 in mice) and vimentin as 
promotors of biliary EMT (OMENETTI et al. 2008; ROBERTSON et al. 2007). These genes were 
significantly upregulated (p< 0.01 for Fsp-1, p< 0.05 for vimentin, p< 0.05 for Igf1r and p< 
0.01 for Crim1) in livers of TAK1LPC-KO mice (Figure 10C). Recently, it has been shown that 
inhibition of Hhip can abrogate experimental biliary EMT (OMENETTI et al. 2008). Gene 
expression analysis of Hhip (p< 0.001) levels in 6 week old TAK1LPC-KO mice revealed a 
significant downregulation (Figure 10C).  
Taken together, these data indicate that TGFβ-driven EMT is crucial for the initiation of 
spontaneous biliary fibrosis of TAK1LPC-KO mice. 
 
 
3.4 Deletion of TAK1 leads to spontaneous apoptosis and hyperplasia 
 
As described above, the livers of 6 week old TAK1LPC-KO mice showed macroscopically 
visible nodules. Those were not seen in age-matched NEMOLPC-KO and WT animals (Figure 
5). The initiation of cancer can be mediated by different factors such as mutations, genomic 
instability, epigenetic modifications or inflammatory processes, leading to tissue repair 
responses, neoangiogenesis and enhanced proliferation (GRIVENNIKOV et al. 2010).  
Initially, we examined deep-frozen liver sections from TAK1LPC-KO, NEMOLPC-KO and WT 
mice for apoptosis by performing TUNEL assay. Evaluation of TUNEL positive hepatocytes 
revealed increased rates of spontaneous death of TAK1 deleted hepatocytes, whereas the 
livers of NEMOLPC-KO showed a lesser extent of spontaneous apoptotic cell death and the 
livers of WT animals showed a normal distribution of apoptotic cells as expected in a healthy 
liver (Figure 11A and B). Additionally, immunohistochemical staining of paraffin-embedded 
liver sections and Western blot analysis of the death protease caspase-3, which catalyses the 
specific cleavage of many key cellular proteins involved in apoptosis (PORTER and JANICKE 
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1999), were performed for all genotypes. Analysis of both experiments demonstrated an 
increased activation of cleaved caspase-3 in livers of 6 week old TAK1LPC-KO mice which 
correlated with the significantly increased cell death highlighted by TUNEL assay. 
Furthermore, Western blot analysis of protein extracts from whole livers derived from 
TAK1LPC-KO mice diplayed strongly elevated expression levels of cleaved caspase-3 compared 
to NEMOLPC-KO and WT animals, confirming enhanced apoptotic activity in livers of 6 week 
old TAK1LPC-KO animals (Figure 11C-E).  
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Figure 11. TAK1 ablation causes spontaneous apoptosis. (A) Spontaneous hepatocyte cell death in 6 week old TAK1LPC-
KO
 and to a minor degree in NEMOLPC-KO, but not WT mice, as demonstrated by TUNEL assay on liver sections (upper 
panels: fluorescence on frozen sections, lower panels: peroxidise staining on paraffin sections, arrows indicate TUNEL+ 
hepatocyte nuclei). (B) Quantification of TUNEL+ hepatocytes in 6 week old mice. Results are shown as mean, and error bars 
indicate SEM. **p< 0.01; ***p< 0.001; n=7 (WT); n=4 (TAK1LPC-KO); n=7 (NEMOLPC-KO). Each dot represents the average 
value per mouse liver, calculated from four high-power-field [HPF] analyses. (C) Immunohistochemical analysis for cleaved 
caspase-3 on liver paraffin sections from 6 week old animals. Positive hepatocytes are marked with arrows. (D) Statistical 
quantification of cleaved caspase-3+ hepatocytes in WT (n=3), TAK1LPC-KO (n=4) and NEMOLPC-KO livers (n=3) (3-4 
measurements / individual liver) based on the immunohistochemical analysis presented in (C). **p< 0.01, ***p< 0.001. (E) 
Western blot analysis on liver protein extracts using an antibody specifically detecting the cleaved form of caspase-3, α-
tubulin served as loading control. 
 
 
A sharp increase in the percentage of apoptotic cells normally leads to a compensatory 
proliferative response of the surrounding cells (GRIVENNIKOV et al. 2010). Thus, BrdU and 
Ki67 immunohistochemical staining of paraffin-embedded liver sections from all genotypes 
was performed. This was to examine the extent of proliferated hepatocytes. The TAK1LPC-KO 
hepatocytes showed massive incorporation of BrdU, as compared to WT hepaotcytes which 
are normally quiescent and therefore none proliferating. Investigation of NEMOLPC-KO 
hepatocytes also revealed increased incorporation of BrdU but to a lesser extent when 
compared to TAK1LPC-KO hepatocytes (Figure 12A and B). Immunohistological examination 
of livers stained for Ki67 demonstrated that the majority of proliferating cells were 
hepatocytes (Figure 12C and D).  
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Figure 12. Enhanced proliferation in TAK1LPC-KO mice. (A) BrdU incorporation analysis to detect S-phase positive cells 
of 6 week old male mice underwent repetitive injections for 2 days (DAPI counterstaining is marked in blue). (B) Statistical 
analysis of BrdU+ cells per HPF. Results are shown as mean, error bars indicate SD. *p< 0.05; **p< 0.01; ***p< 0.001 (n=3). 
(C) Immunohistochemical staining for the proliferation marker Ki67 on liver paraffin sections from 6 to 9 week old mice 
with the indicated genotypes. Inset: positive hepatocyte nuclei on higher magnification. (D) Densitometric analysis of Ki67+ 
hepatocytes per HPF. Results are shown as mean, error bars indicate SEM. *p< 0.05; ***p< 0.001; n=6 (WT); n=4 
(TAK1LPC-KO), n=6 (NEMOLPC-KO); 10 HPF/mouse. (E) Western blot analysis on liver protein extracts from 6 week old mice 
with the indicated antibodies, specific for cell cycle markers. GAPDH serves as loading control. (F) Histological appearance 
of a nodular area of hepatocyte-nuclei in dysplastic areas of TAK1LPC-KO livers compared with WT and NEMOLPC-KO livers. 
 
 
Moreover, Western blot analysis of the key cell-cycle markers for G1-S-phase transition 
cyclin D1, cyclin E1 and PCNA revealed strongly increased expression in whole livers of 
TAK1LPC-KO and NEMOLPC-KO mice, underlining the correlation between hepatocyte death 
and compensatory hyperproliferation in these animals (Figure 12E). In addition, several 
dysplastic nodules in the livers of TAK1LPC-KO mice were observed. These dysplatic fields 
were located within nodular structures and were characterized by anisokaryosis (Figure 12F). 
These modifications were not detected in WT or in NEMOLPC-KO mice (Figure 12F).  
 
 
3.5 TAK1 deletion in liver parenchymal cells promotes early onset of 
hepatocarcinogenesis  
 
Based on the finding of several small nodules on the surface of the 6 week old TAK1LPC-KO 
livers we aimed at clarifying the origin of the tumours by investigating mRNA expression 
levels of two established tumour markers, AFP and H19 (Figure 13) (ARIEL et al. 1998; 
OKUDA 2000). Remarkably, despite no histologically dectectable malignat tumours, TAK1LPC-
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KO
 mice showed strongly increased mRNA expression levels of AFP and H19 in sharp 
contrast to WT and NEMOLPC-KO animals. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13. Dramatically increased expression of tumour markers in TAK1LPC-KO mice. RT-PCR analysis on the 
expression of α-fetoprotein (AFP) and H19. All values are normalized to β-actin expression. Results are expressed as mean, 
and error bars denote SEM. *p< 0.05; **p< 0.01 (n=5 each genotype). 
 
 
These results prompted us to further analyze TAK1 livers for the presence of HCC 
progression. Thus, paraffin-embedded liver sections from 16 to 33 week old TAK1LPC-KO 
mice (5 males and 11 females) were immunohiostochemically analysed by H/E, reticulin and 
collagen IV (Figure 14A and B). Reticulin and collagen IV are important members 
contributing to cross-linking a fine meshwork for maintaining normal liver architecture and 
cellular structure. 
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Figure 14. HCC development in 16 to 36 week old TAK1LPC-KO mice. (A) Histological characteristics of different tumours 
in 16 to 36 week old TAK1LPC-KO mice stained by H/E (left panel, arrow head). Liver tumour with a ‘clear cell like’ 
appearance. The middle and right panels show liver tumours (arrow head) of a size up to 4 mm with eosinophilic cells. (B) 
Consecutive slides of a representative liver tumour in a 20 week old TAK1 mouse stained with H/E, collagen IV, and silver 
reticulin, showing typical histological features of human HCC: expansive growth, increased cellularity, loss of collagen IV 
staining between neighbouring hepatocytes and abnormal architecture, and loss of reticulin fibers. 
 
 
H/E staining of a representative liver tumour demonstrated the obvious modification of liver 
architecture within liver tumours (Figure 14A). This altered tissue is characterized by 
enhanced reduction of blood vessels, bile ducts and periportal fields, but increased cellularity. 
The tissue is arranged as a compact cell mass without regular structures due to the loss of 
collagen IV and reticulin fibers. The unaffected liver tissue is clearly separated from the 
tumorous tissue by a boundary composed of the collagen from the unaffected tissue (Figure 
14B). It was found that 14 of 16 TAK1LPC-KO mice developed liver tumours, which were 
histologically classified as HCC (≈ 88% incidence) based on the following criteria: expansive 
and tissue infiltrating growth pattern, frequent hepatocyte mitosis, increased cellularity, 
nodular structures, broadening and loss of the regular collagen IV and reticulin network 
separating neighbouring hepatocytes. Notably, no HCC or liver tumours were detected in 21 
to 26 week old NEMOLPC-KO mice (n=6) (Figure 15 and Table A1), which normally develop 
HCC by the age of approximately 50 weeks (LUEDDE et al. 2007).  
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Figure 15. Regular liver architecture and distribution of collagen IV and reticulin in liver tissue of 25 week old 
NEMOLPC-KO mice. Histological analysis, collagen-IV staining and reticulin staining revealed no HCC-specific patterns. 
 
 
 
The early onset of HCC warranted a closer examination of the tumour cells. For that reason an 
aCGH analysis was performed (Figure 16). Thus, areas of HCC from TAK1LPC-KO (n=19) 
mice together with corresponding areas from age-matched WT livers (n=8) were 
microdissected. This analysis revealed chromosomal aberrations in all 19 TAK1LPC-KO 
samples, which indicated that the excised tumour tissue was malignant. Amplifications and 
deletions of chromosomal regions ranged from 0.68 megabase (MB) to 151 MB. Remarkably, 
the pattern of chromosomal aberration showed a common signature in all HCC isolated from 
individual TAK1LPC-KO mice (permutation test, p<0.00001). Additionally, it was shown that 7 
of 19 HCC displayed amplifications on chromosome 4, 14 of 19 HCC showed amplifications 
on chromosome 8, and 17 of 19 HCC demonstrated amplifications on chromosome 13.  
Taken together, the detected chromosomal aberrations on chromosome 4, 8 and 13 in HCC of 
TAK1LPC-KO mice maintain the hypothesis of a functional relationship between TAK1-
dependent signals and chromosomal integrity in hepatocytes.  
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Figure 16. Distinct chromosomal aberrations in HCC of TAK1LPC-KO mice. aCGH analysis of HCC from independent 
TAK1LPC-KO mice. The q-arm of each chromosome is shown and chromosome numbers are indicated. Dark horizontal bars 
within the symbolized chromosomes represent G bands. Chromosomal deletions are indicated in blue, and amplifications in 
red. HCC of individual TAK1LPC-KO mice were hybridized against liver tissue of an age-matched WT mouse and analyzed by 
aCGH analysis. Columns next to each chromosome represent individual HCC. Individual mice are labelled by horizontal 
coloured bars (TAK1LPC-KO tumours: n=19; WT liver samples: n=8).  
 
 
Further on, we analysed mRNA expression patterns of 72 well established oncogenes and 
tumour suppressor genes in tissues of the microdissected HCC from TAK1LPC-KO mice in 
relation to unaffected tissue samples (Table A2). With this experiment we wanted to clarify if 
the detected amplifications and deletions are of functional relevance. Among others the 
analysis revealed significant upregulation of the oncogenes FgR and Jun (chromosome 4), 
FgfR1 (chromosome 8), Ntrk2 and Net1 (chromosome 13), as compared to WT livers 
(evaluated by t-test) (Figure 17 and Table A2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17. TAK1 deletion leads to significantly upreglation of oncogens and tumour-suppressor genes in 
microdissected HCC. Analysis of mRNA expression of the selected oncogenes Net1, Ntrk2, FgfR1, Jun and FgR located 
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onchromosome 4, 8, and 13. Asteriks indicates oncogenes that were significantly upregulated after multiple comparisons 
(Bonferroni correction) (see Table 2). High expression levels are represented in red colours and lower expression levels in 
green colours. 
 
 
Multiple comparison with Bonferroni correction verified significant upregulation for Nrtk2 
(20.58-fold), Net1 (6.66-fold), and Jun (2.81-fold) (Table A2), which are all located on 
affected chromosomes discovered by the aCGH array. However, many other oncogenes and 
tumour-suppressor genes involved in HCC development, such as p53, c-myc, n-ras, were not 
significantly dysregulated (Table A2). Both, the analysis of the mRNA expression levels of 
different oncogenes and tumour suppressorgenes and our aCGH-analysis, strengthend the 
hypothesis of a potential link between ablation of TAK1 in liver parenchymal cells and 
detected amplifications which might be responsible for enhanced expression of different 
oncogenes.  
Finally, we wanted to elucidate if the detected HCCs can be classified as malignant tumours. 
Therefore, a quantitative real-time polymerase chain reaction with a 16-gene signature, that 
identifies and groups liver tumours according to their degree of differentiation and 
proliferation rate, was performed (Figure 18) (CAIRO et al. 2008). Unaffected liver samples, 
NEMOLPC-KO liver samples and additionally, samples of aggressive liver tumours from 
WHV/N-myc2 p53+/delta mice served as internal controls (RENARD et al. 2000). Analysis of 
the results revealed co-clustering of nearly all TAK1LPC-KO and NEMOLPC-KO nodules with 
control tumour samples. The heat map showed mRNA upregulation of genes involved in 
proliferation and cell cycle (e.g. Afp, Bub1, Dlg7) accounting for a highly transformed 
molecular phenotype, whereas the controls displayed a clear differentiated phenotype. In 
summary it can be stated that TAK1LPC-KO liver tumours can be classified as malignant HCC. 
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Figure 18. RT-PCR analysis of selected genes revealed malignancy of HCCs from TAK1LPC-KO mice. A 16-gene profile 
analysis (heat map) of HCC derived from TAK1LPC-KO (20 to 31 week old mice) and NEMOLPC-KO livers (52 week old mice). 
HCC were compared to aggressive liver tumours from WHV/N-myc2 p53+/Delta mice. Above the dashed white line the 
genes indicating a proliferative phenotype are listed, whereas genes below the dashed white line represent a less proliferative, 
more differentiated phenotype. 
 
 
3.6 TAK1 controls hepatocyte apoptosis and necrosis via distinct NF-κB independent 
pathways 
 
In the previous experiments we demonstrated that the ablation of TAK1 in liver parenchymal 
cells leads to an early development of hepatocarcinogenesis when compared to the NEMO 
phenotype, which developed late HCC by 52 weeks of age (LUEDDE et al. 2007). Thus, we 
wanted to investigate which molecular pathways downstream of TAK1 are involved in 
mediating this earlier phenotype. LPS is a potent inducer of endogenous TNF secretion (LEIST 
et al. 1995) and intraperitoneal (i.p.) LPS-injection of each genotype was performed. Western 
blot analysis of whole liver extracts from TAK1LPC-KO as well as NEMOLPC-KO mice revealed 
inhibited degradation of the NF-κB inhibitor IκBα, whereas in WT mice strong degradation of 
IκBα was detected (Figure 19A). This result was additionally confirmed by EMSA, which 
demonstrated a strong increase in the translocation of cytoplasmic NF-κB to the nucleus 1 
hour after LPS injection in WT mice, while TAK1LPC-KO and NEMOLPC-KO animals showed 
only a moderate activation of NF-κB (Figure 19B). After 2 hours of LPS injection no 
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translocation into the nucleus of NF-κB was detectable in TAK1LPC-KO mice. Taken together, 
deletion of TAK1 in liver parenchymal cells prevents the degradation of IκBα thereby 
abolishing the activation of NF-κB. A similar result was observed in NEMO ablated liver 
parenchymal cells, leading to the theory that TAK1 and NEMO act in a linear signalling 
cascade to mediate NF-κB activation in hepatocytes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19. Deletion of TAK1 inhibits NF-κB activation after LPS stimulation. (A) Degradation of IκBα and 
phosphorylation of Jun-terminal-kinase (JNK) was examined by Western blot analysis on liver extracts from WT, TAK1LPC-
KO
, and NEMOLPC-KO mice at indicated time points after stimulation with LPS. (B) Electrophoretic mobility shift assay 
(EMSA) on nuclear protein extracts from WT, TAK1LPC-KO, and NEMOLPC-KO livers at the indicated time points after LPS 
stimulation. In lane 10 and 11, antibodies against the NF-κB subunits p50 and p65 were added as supershift control. NF-κB 
activation in response to LPS injection is inhibited in TAK1LPC-KO and NEMOLPC-KO compared to WT livers. 
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Normally, long term activation of JNK is associated with induction of cell death (PAPA et al. 
2004a). JNK was strongly activated in TAK1LPC-KO mice 2 hours after LPS injection and to a 
lesser extent in NEMOLPC-KO, whereas no activation was seen in WT animals (Figure 19A). 
Additionally, primary hepatocytes were isolated and stimulated with recombinant TNF 
(Figure 20). In correlation with the massive hepatocyte cell death noticed in vivo, primary 
hepatocytes isolated from TAK1LPC-KO and NEMOLPC-KO mice showed severe morphological 
alterations in vitro. These cells are characterized by a short life time and were immediately 
stimulated with TNF after cell adhesion. RT-PCR analysis of the NF-κB target genes IκBα 
and A20 (inhibitor of TNF mediated JNK activation (PAPA et al. 2004a) revealed strong 
reduction of mRNA expression levels in hepatocytes of TAK1LPC-KO and NEMOLPC-KO when 
compared with WT hepatocytes (Figure 20). These results indicated that TAK1 and NEMO 
act in a linear pathway to activate NF-κB, whereas ablation of one of them led to a 
hyperactivation/long term activation of JNK which ends in enhanced cell death. This strong 
activation of JNK might cause significant downregulation of the JNK-inhibitor A20 (Figure 
19A and B). Moreover, JNK is an important mediator of hepatocarcinogenesis (SAKURAI et 
al. 2006), corroborate the theory that hyperactivation of JNK in TAK1LPC-KO livers in 
response to LPS might be an important mediator of the prodysplastic phenotype seen in these 
animals. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20. No activation of NF-κB target genes in TAK1- and NEMO-deficient hepatocytes. Induction of NF-κB target 
genes A20 and IκBα in response to TNF stimulation was examined in primary hepatocytes isolated from WT, TAK1LPC-KO, 
and NEMOLPC-KO mice by quantitative RT-PCR. Results are expressed as mean, and error bars denote SD (n=3 each 
genotype). 
 
 
Recent studies have demonstrated that only complete but not partial inhibition of inducible 
NF-κB activation sensitizes hepatocytes to LPS-induced apoptosis (LUEDDE et al. 2007). 
Thus, the apoptotic response following LPS stimulation was compared in TAK1LPC-KO and 
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NEMOLPC-KO mice (Figure 21A-C). Corresponding with the blockage of NF-κB activation 
(Figure19A and B), hepatocytes of TAK1LPC-KO mice showed massive apoptosis and liver 
damage 9 hours after LPS treatment similar to NEMOLPC-KO mice (Figure 21C). This was also 
demonstrated by TUNEL assay and Western blot analysis for cleaved caspase-3 which was in 
line with the massive increased blood serum ALT levels from TAK1LPC-KO and NEMOLPC-KO 
animals (Figure 21A-C).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21. TAK1 is associated in caspase-3 dependent hepatocyte apoptosis. (A) TUNEL assay on liver sections from the 
indicated mouse lines at 9 hours after LPS injection (original magnification x 200). (B) Western blot analysis on whole liver 
extracts isolated from each phenotype after LPS injection using antibody against the cleaved form of caspase-3 or GAPDH as 
loading control. (C) Liver injury 9 hours after LPS treatment was assessed by measuring serum ALT. Results are expressed 
as mean, and error bars indicate SD. *p< 0.05; **p< 0.01, ***p< 0.001 (n=3 each phenotype). 
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Beside TAK1 there are also other MAP3Ks such as MEKK3 and TAO2 playing an important 
role in mediating apoptosis and cell differentiation in different cell types (CHEN et al. 2003; 
HUANGFU et al. 2006; YAMAZAKI et al. 2009). Under certain conditions thousand-and-one 
amino acid kinase 2 (TAO2) mediates activation of JNK by phosphorylating MKK4 and 
MKK7 (HUANGFU et al. 2006). Moreover, TAO2 is able to associate with TAK1 and thereby 
inhibiting TAK1-mediated activation of NF-κB but not of JNK (HUANGFU et al. 2006). 
Western blot analysis of whole protein lysates from LPS injected TAK1LPC-KO and NEMOLPC-
KO
 mice revealed a strong activation of the MAPK kinase MKK4 1 hour following injection, 
which correlated with the simultaneous activation of its activator TAO2 (Figure 22). 
Interestingly, WT mice displayed very slight activation of MKK4 and TAO2, which suggests 
that other MAP3Ks than TAK1 are also involved in mediating apoptotic pathways in 
hepatocytes. 
 
 
 
 
 
 
 
 
 
 
Figure 22. The TAO2-MKK4/7 axis represent an additional pathway for activating JNK. Immunoblot analysis on 
whole liver protein extracts isolated from the indicated mouse lines after LPS injection using antibodies detecting the 
phosphorylated forms of MKK4 and TAO2 using GAPGH as loading control. 
 
 
Consistent with its pro-survival function through cytoplasmic IκBα degradation and 
subsequent NF-κB activation, IKK-β also phosphorylates and triggers the nuclear exclusion 
and the cytoplasmic- and proteasome mediated proteolysis of the forkhead transcription factor 
FOXO3a (HU et al. 2004). FOXO3a functions as a trigger for apoptosis and is known as a 
tumour-suppressor. Apart from IKK-β, the kinase AKT is another important negative 
regulator of FOXO3a. Liver protein lysates from 6 week old WT, TAK1LPC-KO and NEMOLPC-
KO
 mice were analyzed and revealed increased activation of FOXO3a in livers of TAK1LPC-KO 
(Figure 23), but not in livers of NEMOLPC-KO mice. The increased activation of FOXO3a was 
not linked with significant changes in phophorylation of the upstream kinase AKT. Since 
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IKK-dependent phosphorylation of FOXO3a has been shown to mediate carcinogenesis in 
many tumours (HU et al. 2004), it is therefore possible that early activation of this pathway 
also contributes to NEMO mediated hepatocarcinogenesis in younger TAK1LPC-KO mice. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23. The FOXO3a pathway contribute to NEMO-mediated heptocarcinogenesis. Immunoblot analysis of total 
FOXO3a, p-AKT, and AKT in liver homogenates of 6 week old TAK1LPC-KO, NEMOLPC-KO and their respective littermate 
control mice. GAPDH was used as loading control. 
 
 
3.7 TAK1 deletion in LPC promotes cholestasis and ductopenia  
 
One of the most intriguing characteristics of TAK1 deletion in liver parenchymal cells was 
the appearance of severe jaundice in these animals (Figure 6). As a consequence liver sections 
from 6 week old TAK1LPC-KO mice were H/E stained and stained for pan-cytokeratin, a 
specific marker for cholangiocytes, to analyse how strong the impact of TAK1 ablation was 
on bile duct architechture and distribution. Histological analysis of H/E stained liver sections 
from 6 week old TAK1LPC-KO animals revealed a severe reduction of bile ducts as compared 
to NEMOLPC-KO and WT animals (Figure 24A). This remarkable finding was additionally 
confirmed by the pan-cytokeratin staining (Figure 24A). Furthermore, morphometric analysis 
of livers from WT and NEMOLPC-KO animals showed normal distribution of bile ducts 
whereas the TAK1LPC-KO livers exhibited a strong reduction of bile ducts (Figure 24B). 
Moreover, analysis of areas of dysplastic hepatocytes versus areas of non-dyplastic areas in 
TAK1LPC-KO livers revealed enhanced reduction of bile ducts in the dysplastic areas, whereas 
pre-existing biliary epithelial cells and bile duct structures were detectable in the border zone 
of dysplastic areas (Figure 24C and D).  
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Figure 24. Severe reduction of biliary epithelial cells in TAK1LPC-KO livers. (A) Hematoxylin and eosin (H/E) 
and cytokeratin (CK) stainings showing the presence of small bile ducts in portal areas of WT and NEMOLPC-KO 
(left and right panel; arrows), but not TAK1LPC-KO livers. (B) Statistical quantification of number of bile ducts 
per 6 mm2 in WT (n=4), TAKLPC-KO (n=4) and NEMOLPC-KO livers (3 measurements / individual liver), **p< 
0.01. (C) Upper panels: no CK+ cells can be detected in the region of an expected portal tract in a TAK1LPC-KO 
liver (right panel) when compared with strongly positive bile ducts in livers of WT mice (left panel). Lower 
panel: detection of CK+ cells and biliary ducts in surrounding a dysplastic nodule of a TAK1LPC-KO liver. (D) 
Evaluation of bile ducts in areas of expanding dysplastic hepatocytes versus areas of non-dysplastic hepatocytes 
by CK staining; WT (n=4); TAK1LPC-KO (n=6), **p< 0.01. 
 
 
 
To investigate the molecular mechanism of ductopenia in TAK1LPC-KO mice co-stainings for 
the biliary epithelial marker CK with cleaved caspase-3, a marker of apoptosis, and Ki67 to 
define proliferation in WT and TAK1LPC-KO mice were performed. These stainings revealed 
proliferation and, to a lesser extent, apoptosis within the portal bile tracts of TAK1LPC-KO mice 
(Figure 25).  
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Figure 25. Deletion of TAK1 in cholangiocytes leads to increased apoptosis and proliferation. Double stainings of CK 
with either cleaved caspase-3 or Ki67 revealed an enhanced proliferation along with apoptosis in the area of small bile ducts 
of TAK1LPC-KO livers (arrows indicate the area of double-stained cells). 
 
 
Moreover, electron microscopy illustrated striking differences and modifications of the bile 
canaliculus architecture in 6 to 8 week old TAK1LPC-KOmice as compared to age matched WT 
controls (Figure 26). The representative picture of a bile canaliculus in a TAK1LPC-KO mouse 
displayed a hugely dilated and irregular lumen combined with the absence of canalicular 
microvilli as compared to a normal canaliculus in the control mouse, indicating that TAK1LPC-
KO 
mice suffer from massive cholestasis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 26. Electron microscopical analysis of bile canaliculi in livers of WT and TAK1LPC-KO mice. The bile canaliculus 
in TAK1LPC-KO mice showed a strongly dilated irregular lumen with disappearance of canalicular microvilli compared with a 
normal canaliculus in control mice, indicating massive cholestasis in TAK1LPC-K mice. 
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Based on the double stainings of pan-cytokeratin with either cleaved caspase-3 or Ki67, we 
confirmed that TAK1 deletion in cholangiocytes causes both, apoptosis and proliferation; 
similar to what was observed in hepatocytes. To further elucidate if TAK1 mediates similar 
pathways in cholangiocytes as compared to hepatocytes laser microdissection was performed. 
Portal tracts of WT and TAK1LPC-KO mice were isolated along with adjacent parenchyma and 
were analysed for differences in gene expression profiles.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 27. Real-time PCR analysis of RNA from laser-dissected A6+oval cells/cholangiocytes derived from WT and 
TAK1LPC-KO livers, as well as WT hepatocytes. Expression of Tak1, Sca-1, Claudin-7, Epcam, Afp, and A20 in 
cholangiocytes/oval cells and hepatocytes is presented as a heat map. 
 
 
To confirm the purity of the laser dissected tissues transcriptional analysis for the expression 
of markers typical for oval cells and intrahepatic biliary epithelial cells, such as Sca-1, 
Claudin-7, and Epcam was performed (Figure 27). These results showed a strong 
upregulation of these markers in portal tracts isolated from WT and TAK1LPC-KO mice but not 
in laser dissected hepatocytes. Further transcriptional analysis revealed an approximately 3-
fold downregulation of Tak1 expression in cholangiocytes/oval cells of TAK1LPC-KO mice 
when compared to WT cholangiocytes/oval cells. This confirmed the expected 
downregulation of TAK1 in all parenchymal liver cell compartments. Similar to the results 
from total livers, mRNA expression of Afp was also significantly upregulated (Figure 27). The 
mRNA expression of Afp was on average approximately 7 times higher in isolated 
cholangiocytes/oval cells from TAK1LPC-KO when compared with WT cholangiocytes/oval 
cells. In contrast, the NF-κB target gene A20 was downregulated on average 2.4-fold in 
cholangiocytes/oval cells from TAK1LPC-KO livers as compared with WT cholangiocytes/oval 
cells (Figure 27). The results were suggestive of the fact that in addition to hepatocyte-
specific effects, cholangiocyte-specific effects of TAK1 ablation also contribute to ductopenia 
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WT chol./oval
TAK1LPC-KO chol./oval
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in TAK1LPC-KO mice and furthermore the deletion of TAK1 in cholangiocytes/oval cells 
affects similar signalling pathways and transcriptional targets as observed in hepatocytes. 
To specify the role of TAK1 in liver we generated mice with specific deletion of Tak1 using 
an alternative solely albumin driven cre-promoter which was postnataly expressed in the 
liver.(POSTIC and MAGNUSON 2000) (TAK1∆hep) (Figure 28).  
 
 
 
 
 
 
 
 
 
 
Figure 28. Western blot analysis with the indicated antibodies on whole liver protein extracts from 8 week old female WT 
and TAK1∆hep mice (left panel). Quantitative RT-PCR analysis on the expression of TAK1 in female WT and TAK1∆hep 
mice (right panel). All values were normalized to β-Actin expression. Results are expressed as mean, error bars denote SEM, 
*p< 0.05; (n=4 each group). 
 
 
TAK1∆hep mice displayed many features to those previously described in TAK1LPC-KO mice 
such as hepatocyte hyperplasia and dysplasia as demonstrated by increased mRNA expression 
level of the pro-oncogene H19 and by strong activation of the key cell cycle markers PCNA 
and Ki67 (Figure 29 A-C). Moreover, serological analysis (Figure 29D) revealed increased 
ALT (240 ± 37 U/l) and AST (378 ± 46 U/l) level but to a lesser extent than in TAK1LPC-KO 
mice (ALT (2180 ± 306 U/l); AST (1518 ± 301 U/l); Figure 5C) indicating that TAK1∆hep 
animals suffered from a mild hepatitis. Additionally, although these animals displayed a mild 
hyperbilirubinemia (2 ± 0.5 mg/dl; Figure 29D) it was not as pronounced as what was 
observed in TAK1LPC-KO (9 ± 0.5 mg/dl; Figure 5C) mice but correlated with areas of 
ductopenia within some portal tracts (Figure 29E). It has been shown that in addition to 
hepatocytes the albumin-cre line can also lead to leaky expression of Cre-recombinase in 
intrahepatic cholangiocytes (XU et al. 2006), indicating that both hepatocyte-and 
cholangiocytes-specific effects of TAK1-deletion contributed to the phenotype in TAK1∆hep 
mice. In contrast to TAK1LPC-KO livers (Figure 24A), some periportal areas in TAK1∆hep 
mice showed several hepatocytes that stained positive for A6, suggesting they originate from 
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A6-positive oval cells (Figure 29E). The detection of increased abundance of immature 
hepatocytes in TAK1∆hep animals was sustained by decreased expression of epithelial 
markers such as Albumin and c/ebpβ (Figure 29F). These results showed that both TAK1∆hep 
and TAK1LPC-KO mice developed a similar phenotype but in contrast to the prenatal 
expression of Alfp-cre in the livers of TAK1LPC-KO mice, the postnatal expression of the Alb-
cre in livers of TAK1∆hep animals caused a milder progression of this severe phenotype.  
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Figure 29. Analysis of TAK1∆hep mice. (A) Quantitative RT-PCR analysis on the expression of H19. All values are 
normalized to β-actin expression. Results are expressed as mean, and error bars denote SEM, *p< 0.05; n= 5 each genotype. 
(B) Western blot analysis with the indicated antibodies of whole liver protein extracts from 8 week old female WT and 
TAK1∆hep mice. (C) Immunohistochemical analysis for Ki67 expression of liver slides from 8 week old female WT and 
TAK1∆hep mice. (D) Serum level analysis of AST, ALT, and total bilirubin in 9 week old TAK1∆hep and WT mice. Results 
are shown as mean, and error bars indicate SEM, **p< 0.01, *p< 0.05 (n=4 each genotype). (E) Histological and 
immunohistochemical analysis of representative liver sections from 9 week old TAK1∆hep mice and WT controls. On A6 
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staining, biliary ducts were absent in some portal tracts but could be detected in others (lower row). In some areas, 
hepatocytes stained strongly positive for A6 (upper right picture). (F) Quantitative RT-PCR analysis of the expression of 
albumin and c/ebpβ in female WT and TAK1∆hep mice. All values were normalized to β-Actin expression. Results are 
expressed as mean, error bars denote SEM, *p< 0.05; (n=4 each group). 
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4. Discussion 
 
The NF-κB signalling pathway is one of the most important mediators of innate immunity and 
inflammation as it links production of cytokines with cellular processes like apoptosis and 
proliferation (BETTERMANN et al. 2010; GRIVENNIKOV et al. 2010; HAYBAECK et al. 2009). 
Chronic inflammation is the main cause of HCC formation. However, the specific function of 
NF-κB in the development of HCC is still not completely elucidated. Moreover, recent studies 
have presented a controversial function of NF-κB in cancer development (BETTERMANN et al. 
2010; HAYBAECK et al. 2009; PIKARSKY et al. 2004). Inhibition of NF-κB by conditional 
expression of the IκBα superrepressor in hepatocytes hinders liver cancer development, 
thereby suggesting a procarcinogenic function of NF-κB (PIKARSKY et al. 2004). Later studies 
targeting the IKK subunits IKKβ and NEMO implied a tumour suppressor function on this 
pathway in hepatocarcinogenesis (LUEDDE et al. 2007). Activation of the canonical and 
noncanonical NF-κB pathways by lymphotoxin promotes hepatocarcinogenesis (Haybaeck 
2009). Thus, the specific roles of NF-κB and the IKK complex remain controversial, and 
might vary depending on the model used (WAGNER and NEBREDA 2009). 
 
 
4.1 TAK1 deletion in LPC causes a strong phenotype 
 
In this study we showed that TAK1 deletion in LPCs initiates the development of a strong and 
spontaneous phenotype. Macroscopic pictures of livers from 6 week old TAK1LPC-KO mice 
revealed several small liver nodules accompanied by a mild icteric appearance. Moreover, 
these animals suffered not only from severe hepatitis but they also displayed progressive 
cholangitis by the age of 6 weeks, which finally lead to an earlier demise. These findings were 
strengthened by significantly elevated blood serum levels of classical indicators of liver 
damage such as AST, ALT, bilirubin, AP and GLDH. The livers of these animals additionally 
displayed advanced periportal fibrosis at 6 weeks of age and showed severe deposition of 
collagen at 28 weeks of age (Figure 8A). Moreover, pan-cytokeratin staining of liver sections 
from 6 to 8 week old TAK1LPC-KO mice revealed a striking reduction of bile duct epithelial 
cells, representing the main cause for the development of lethal cholangitis. Another 
important aspect of this phenotype was the development of HCC in the period of 14 to 36 
weeks of age, which is considerably earlier than what was observed in the NEMOLPC-KO mice 
which developed HCC by 52 weeks of age (LUEDDE et al. 2007). In summary, this phenotype 
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is characterized by 5 major characteristics: severe hepatitis, lethal cholangitis, fibrosis, 
ductopenia and the development of early developing hepatocellular carcinoma.  
 
 
4.2 TAK1 and NEMO are both required for NF-κB activation 
 
The examination of blood samples from 6 week old TAK1 mice revealed significantly 
increased ALT and AST values as compared to NEMOLPC-KO and WT animals, indicating that 
these animals suffered from severe hepatitis. Next, we wanted to evaluate which causes are 
responsible for the development of acute hepatitis in TAK1LPC-KO mice and to a milder 
progression in NEMOLPC-KO animals.  
As under normal conditions mice do not live in a sterile environment, they are continuously 
exposed to small doses of LPS, originating from the commensal intestinal bacteria. LPS 
reaches the liver via the portal vein, where this endotoxin induces cytokine production 
(ENOMOTO et al. 2002). LPS mediates its cytotoxic effects on hepatocytes solely by TNF and 
its receptors (LEIST et al. 1995). Mice used for this study were not kept under sterile 
conditions which may explain the strongly upregulated mRNA expression level of TNF in 
TAK1LPC-KO and NEMOLPC-KO mice. It is therefore possible that TNF and maybe other TNF 
family members are involved in the onset of spontaneous hepatitis and apoptosis in both 
mouse lines (Figure 5C and 11A-E). This correlates with the recent work from Inokuchi and 
co-workers, which demonstrated that additional deletion of TNFR1 is able to reduce liver 
damage and inflammation in mice with TAK1 deficient livers (INOKUCHI et al. 2010).  
Another important aspect was the finding that TAK1 and NEMO are both needed for the 
activation of NF-κB upon LPS stimulation. LPS initiates an acute inflammatory reponse via 
the TLR4 and TNFR pathway (LEIST et al. 1995; SATO et al. 2005). This leads to the 
activation of NF-κB and after its translocation to the nucleus, activation of several hundreds 
of proinflammatory genes containing κB-binding sites. Notably, LPS-stimulated livers of 
TAK1LPC-KO and NEMOLPC-KO mice revealed defective activation of NF-κB (Figure 19A and 
B). Furthermore, TNF-stimulated primary hepatocytes showed reduced expression levels of 
the NF-κB target genes Iκbα and A20 (Figure 20). This leads to the suggestion that TAK1 and 
NEMO are both crucial for the activation of NF-κB. Both molecules appear to be directly 
connected with each other in order to prevent apoptosis and liver failure. However, it is still 
unclear which molecules are involved in mediating close interaction between TAK1 and 
NEMO. It is generally thought that assembly of ubiquitin-dependent signalling complexes  
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equally activate TAK1, whereby TAK1 efficiently phosphorylates and activates IKKβ (SUN 
and LEY 2008). Furthermore, it was shown by recent studies that in TNF-stimulated cells 
TRAF2, one component of the TNFR-complex I, mediates K63 ubiquitination of the adaptor 
kinase RIP1, which in turn recruits TAK1 and the IKK complex (especially NEMO) to 
TRAF2 (EA et al. 2006; LI et al. 2009) and finally to the TNFR-complex I. A similar 
mechanism for the recruitment of TAK1 in the TLR/IL-1 receptor signalling pathway was 
described; there TRAF6 serves as recruiting molecule for TAK1 (CHEN 2005). This implies 
that the kinase function of TAK1, the ubiquitination of NEMO and their subsequent 
recruitment to RIP1 are needed for phosphorylating the catalytic subunits IKKα and IKKβ.  
 
 
4.3 Deletion of TAK1 or NEMO in liver parenchymal cells causes hyperactivation of 
JNK 
 
As mentioned above, ablation of TAK1 and NEMO in the liver causes abolished activation of 
NF-κB. As a consequence, administration of LPS or TNFα leads to enhanced activation of 
proapoptotic pathways. It is well established that the cross-talk between NF-κB and JNK 
activity plays an important role in the fate of hepatocytes upon TNFα challenge (SCHWABE et 
al. 2006). Here, western blot analysis of LPS stimulated livers from TAK1LPC-KO and 
NEMOLPC-KO animals showed that the absence of NF-κB enables a prolonged activation of 
JNK (Figure 19A) which correlated with enhanced numbers of TUNEL+ hepatocytes, strongly 
increased expression of cleaved caspase-3, and significantly elevated ALT levels (Figure 
21A-C). It is believed that long-lasting rather than transient activation of JNK is responsible 
for mediating apoptosis. Thus, NF-κB-mediated suppression of JNK activation is crucial for 
inhibition of TNFα induced cell death (DE SMAELE et al. 2001; PAPA et al. 2004b; TANG et al. 
2001). NF-κB essentially controls JNK activation by inducing the expression of the upstream 
located regulatory proteins A20 and GADD45β (PAPA et al. 2004a ). The stimulation of 
primary hepatocytes with recombinant TNFα revealed reduced mRNA expression levels of 
Iκbα and A20 (Figure 20). Generally, A20 is rapidly induced by TNFα (BEG and BALTIMORE 
1996; KUCHARCZAK et al. 2003) and its downregulation represents one possibility for 
hyperactivating of JNK. Impeding of NF-κB activation by ablation of RelA (p65), IKKβ or by 
expression of IκBα-superrepressor was reported to abolish determination of TNFα induced 
JNK signalling (PAPA et al. 2004b). 
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The importance of the catalytic subunits IKKα and IKKβ has been reported for the interaction 
of IKK with TRAF2 (Devin 2001). Accordingly, IKKα or IKKβ alone is sufficient for the 
recruitment of IKK to TNFR1. Importantly, this study demonstrated a NEMO independent 
IKK recruitment to TNF-R1, suggesting that NEMO stabilizes the IKK complex during its 
interaction with TRAF2. This might imply that ablation of NEMO leads to inactivation of 
NF-κB and thereby promoting a prolonged JNK activation via the TRAF2-TAK1-MKK4 axis 
(Figure 22).  
Another theory for the hyperactivation of JNK in LPS stimulated livers of TAK1LPC-KO and 
NEMOLPC-KO mice may be the participation of other MAP3Ks in activation of JNK. There are 
four major MAP3K groups: the MEKK group (MEKK1/2/3/4), the TAO group (TAO1/2/3), 
the ASK group (ASK1 and ASK2) and TAK1. Many of these MAP3Ks can activate more 
than one MAPK pathway and are able to mediate activation of the NF-κB and JNK pathway, 
highlighting the complexity of this signalling response (DAVIS 2000). Recent reports have 
emphasised an important role for MEKK3 and TAO2 in initiating JNK and NF-κB signalling 
cascades (CHANG and KARIN 2001; SATO et al. 2005; YAMAZAKI et al. 2009).  
In line with these findings, we verified an increased activation of TAO2 in LPS treated liver 
extracts from TAK1LPC-KO and NEMOLPC-KO mice. We observed a prolonged activation of 
TAO2 in LPS-stimulated TAK1LPC-KO livers. Remarkably, these liver extracts revealed a 
much more intense TAO2 activation 2 hours after LPS injection when compared to liver 
extracts from NEMOLPC-KO mice. TAO2 is an important regulator of TAK1 activation under 
certain conditions as previously demonstrated (HUANGFU et al. 2006). Thus, TAO2 associates 
with TAK1, which impedes TAK1 mediated activation of NF-κB but does not affect JNK 
activation (HUANGFU et al. 2006). The deletion of TAK1 might have the consequence that 
TAO2 mainly phosphorylates MKK4/7, leading to enhanced activation of JNK. Furthermore, 
enhanced expression of TAO2 is mainly influenced by reactive oxygen species (ROS) 
(HUANGFU et al. 2006), which are generated during increased apoptotic processes. In our 
study we detected increased aopotosis and enhanced expression levels of TAO2 in untreated 
as well as in LPS-stimulated livers of TAK1LPC-KO mice, indicating that there is a correlation 
between enhanced apoptosis and increased TAO2 expression in the these livers.  
This is in line with previous reports, suggesting ROS-mediated suppression of MKPs is 
thought to impair downregulation of the JNK cascade following exposure to TNF-α, thus 
prompting sustained activation of JNK and therefore enhanced apopotosis (KAMATA et al. 
2005; KARIN 2006). 
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Oxidative stress and enhanced ROS activation induce another MAP3K, ASK1 which in turn 
activates JNK (MATSUKAWA et al. 2004).  
NF-κB activation has been shown to be coordinated by an early and late initiation step. The 
authors demonstrated that the early and transient activation of NF-κB depends on MEKK3, 
TRAF6, TAK1 and its specific adapter proteins TAB2/3 whereas the late and sustained 
activation of NF-κB is only mediated by MEKK3 and the IKK complex, notably without 
TAK1. Especially the late step establishes continuous activation of NF-κB, which is required 
for the production of sufficient cytokines (YAMAZAKI et al. 2009).  
The results from this study support the theory of a MEKK3 triggered NF-κB activation in 
TAK1LPC-KO livers 1 hour after LPS injection, whereas this effect was not detectable in 
NEMOLPC-KO livers due to an impaired activation of NF-κB. The current literature 
recommends that more than one MAP3K is involed in mediating hyperactivation of JNK in 
liver parenchymal cells lacking TAK1 or NEMO (Figure 11A-E). The enhanced hepatocyte 
cell death in livers of TAK1LPC-KO animals argue for an increased ROS production, leading to 
the activation of MKK4/7 and TAO2 and finally JNK. ROS seems to be involved in inducing 
other MAP3Ks such as ASK1 and/ or MEKK3 and simultaneously in inhibition of MKPs.  
Moreover, the shift in the activation of JNK as well as the slight NF-κB expression in 
TAK1LPC-KO livers (Figure 19A and B) may be the result of a transient activation of NF-κB.  
 
 
4.4 TAK1 and NEMO deletion promotes the development of fibrogenesis and EMT 
 
TRAF2 and TRAF6 play an important role in TAK1 activation thereby we asked if a similar 
signalling cacscade is activated in the Smad independent pathway of TGF-β signalling. TGF-
β activates JNK through the MAP kinase pathway independently from Smads role in 
induction of apoptosis during normal physiological processes, in tumour suppression and in 
promotion of EMT at the onset of metastasis (DERYNCK and ZHANG 2003; MOUSTAKAS and 
HELDIN 2005). It was also demonstrated by using TAK1-deficient mouse embryonic 
fibroblasts that TAK1 is definitely required for TGF-β-induced JNK and NF-κB activation 
(SHIM et al. 2005). Our investigation demonstrates significantly increased mRNA expression 
levels of all three isoforms of TGF-β (Figure 9B), suggesting that activation of TGF-β 
signalling may also play an important role in JNK hyperactivation in addition to its classical 
function as a promoter of fibrogenesis and EMT.  
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Analysis of Sirius red stained liver sections from 6 and 28 week old TAK1LPC-KO and 
NEMOLPC-KO animals revealed strongly increased deposition of collagen fibers (Figure 8A). 
The TGF-β signalling pathway is the most prominent pathway driving fibrogenesis 
(BATALLER and BRENNER 2005). Activated TGF-β stimulates the expression of many ECM 
proteins and further prevents the degradation by MMPs due to the upregulation of TIMPs in 
HSCs and myofibroblasts (IREDALE 1997; IREDALE et al. 1992). This was demonstrated in 
transgenic mice, which develop multiple tissue lesions including hepatic fibrosis and 
hepatocyte apoptosis due to an overexpression of active TGF-β1 in the liver (KANZLER et al. 
1999; SANDERSON et al. 1995). Furthermore, other studies have revealed that liver 
regeneration and fibrogenesis are accompanied by an upregulation in expression of all three 
TGF-β isoforms (BISSELL et al. 1995), This corresponds with our findings of significantly 
increased mRNA expression levels of TGF-β1, 2 and 3 as well as the enhanced expression of 
activated Smad 2, Smad 2/3 and Smad 3 (Figure 9B-D). Smad2 or Smad3 binds to the 
activated TGF-β receptor complex, becomes phosphorylated, and forms oligomeric 
complexes with Smad4. These complexes translocate into the nucleus where they bind to 
specific DNA-binding sites. This binding changes the transcriptional activity of genes that 
encode extracellular matrix proteins, such as the α1 and α2 chains of type I collagen, or of 
extracellular matrix regulatory proteins, such as connective tissue growth factor 
(ROSENBLOOM et al. 2010).  
Furthermore, it has been demonstrated that persistent oxidative stress combined with ROS 
production represents a fundamental event in hepatic fibrogenesis, leading to activation of 
HSC and expression of MMP and TIMP (POLI 2000). Taken together, TGF-β seems to be one 
of the driving forces of fibrogenesis in TAK1LPC-KO and NEMOLPC-KO mice. Moreover, TGF-
β may also play an important role in mediating hyperactivation of JNK during LPS 
stimulation of livers from both TAK1LPC-KO and NEMOLPC-KO animals. 
Another important event in liver physiology is EMT. Therefore, we asked whether TGF-β 
activation has the ability to induce EMT in livers of TAK1LPC-KO and NEMOLPC-KO mice. 
EMT represents the convergence point between inflammation and the progression of 
degenerative fibrotic diseases and cancer. The process of EMT is characterized by the 
deficiency in cell polarity and a change in cell shape from cuboidal to fibroblastoid, combined 
with downregulation of epithelial markers and an upregulation of mesenchymal markers 
(KALLURI 2009; THIERY et al. 2009). Consistent with their binding to the same receptor 
complexes, TGF-β1, TGF-β2 and TGF-β3 all share the capacity to induce EMT in epithelial 
cells and represent, along with ROS, one of the most potent inducers of this process (XU et al. 
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2009). TGF-β1-induced EMT programme promotes the remodelling of the cell contacts 
within the basal membrane by activating the matrix metalloproteases MMP-2 and MMP-9 
(KALLURI and NEILSON 2003), leading to the degradation of the collagen type IV component 
of the basement membrane. TGF-β2 has been shown to be essential for the initiation of the 
EMT program and for the separation of endothelial cells, whereas TGF-β3 was shown to be 
specifically required for the migration of the separated endothelial cells into ECM (BOYER et 
al. 1999). 
As mentioned above, we show that there is a spontaneous upregluation in mRNA expression 
levels of all three TGF-β isoforms in TAK1LPC-KO and, to a lesser extent in NEMOLPC-KO 
animals, which is highly suggestive for the likelihood of EMT in these livers. Quantitative 
RT-PCR analysis of Hey1 (Notch signalling pathway) and Snail1 (Wnt signalling pathway), 
which are both important transcription factors in mediating EMT, revealed significant 
upregulation in livers of TAK1LPC-KO as compared to WT livers, whereas the hepatocyte 
specific epithelial marker cEBP/β was significantly downregulated on RNA level in livers of 
TAK1LPC-KO animals (Figure 10A). 
The transcription factor Snail downregulates the expression of other epithelial molecules like 
claudins and occludins and induces the expression of genes associated with a mesenchymal 
and invasive phenotype, such as fibronectin, vimentin and MMP-9. The expression of Snail is 
regulated by a complex signalling network including several different signalling pathways 
such as phosphatidylinositol 3-kinase (PI3-K), MAPKs, and NF-κB pathways (DE CRAENE et 
al. 2005). 
Immunohistochemical co-stainings with the tight junction associated proteins occludin and 
ZO-1 revealed conspicuous changes in the cellular architecture (Figure 10B) which is 
consistent with typical findings in tissues undergoing TGF-β-dependent EMT (XU et al. 
2009). Occludin is one important component of the intercellular tight junction strands, while 
the cytoplasmic component ZO-1 is connected to an undercoat structure. The cytoplasmic 
tails of ZO proteins attach to actin filaments, thereby contributing to the strength and integrity 
of tight junctions, which in turn are crucial for providing intercellular sealing and protection 
against paracellular diffusion, and separate the distinct functions of the apical and basolateral 
surfaces (TSUKITA et al. 2001). The results presented here show a completely disturbed 
distribution of occludin and ZO-1 in liver tissue from TAK1LPC-KO mice and therefore provide 
an explanation for the nearly complete abolishment of cell to cell interaction within the 
affected areas. Moreover, it is likely to conclude that a normal exchange of metabolites and 
various molecules between hepatocytes is no longer functional.  
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Another critical point is that the phosphorylation of SMAD2 and the expression of the EMT 
associated genes S100A4 (Fsp-1 in mice) and vimentin represent early steps of primary biliary 
cirrhosis in patients (ROBERTSON et al. 2007). Recent experiments of induced biliary fibrosis 
in mice have identified Igf1r and Crim1 as additional genes involved in promoting biliary 
EMT (OMENETTI et al. 2008). These genes were significantly upregulated in livers of 
TAK1LPC-KO mice, suggesting evidence for EMT induced jaundice (Figure 10C). Another key 
player in EMT is the Hedgehog signalling pathway. Inhibition of Hedgehog signalling via 
Hhip can abrogate experimental biliary EMT (OMENETTI et al. 2008). In our study, Hhip was 
spontaneously downregulated in 6 week old TAK1LPC-KO mice (Figure 10C).  
Interestingly, recent studies argue for a role of JNK in TGF-β induced EMT. In these 
experiments using epithelial cells, keratinocytes were transfected with antisense 
oligonucleotides targeting JNK, revealed inhibition of EMT upon TGF-β treatment (ALCORN 
et al. 2008; SANTIBANEZ 2006). This study together with the work of Han may reveal an 
potent role for JNK in cytoskeleton organization, cell migration and invasion through the 
regulation of MMP expression (HAN et al. 2006).  
Taken together, the TGF-β signalling pathway seems to be not only involved in fibrogensis 
but also in promoting EMT in livers of TAK1LPC-KO animals. This study presents very 
promising arguments for EMT by demonstrating increased levels of typical markers like 
Snail, Hey1, vimentin, S100A and the loss of occluding and ZO-1.  
However, analysis of mRNA expression levels of additional mediators of EMT such as 
occludin 23 and desmoplakin revealed non-significant changes. Furthermore, we could not 
detect significantly reduced mRNA expression levels of E-cadherin, the key player of EMT.  
Of note, we have demonstrated that TAK1 plays a role in EMT, however, presently it is not 
completely defined whether hepatocytes from TAK1LPC-KO mice undergo EMT. Nevertheless, 
these data argue for a concomitant effect of severe fibrosis and further experiments are needed 
to evaluate if livers from NEMOLPC-KO and TAK1/NEMOLPC-KO animals show features of 
EMT as well.  
 
 
4.5 TAK1 deletion in LPC leads to Dysplasia and Ductopenia 
 
One of the most important findings was the detection of severe cholangitis accompanied by 
jaundice in 14 to 36 week old TAK1LPC-KO mice finally leading to death (Figure 5B and C, 6B 
and C, Figure 7). Examination of H/E and pan-cytokeratin stained liver sections from 6 to 8 
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week old TAK1LPC-KO mice reaveled severe reduction of biliary epithelial cells (Figure 24A-
D). In contrast, the liver tissues from NEMOLPC-KO and WT mice showed a normal 
distribution of cholangiocytes (Figure 24A).  
The performed co-staining for a biliary marker (CK) together with a proliferation marker 
(Ki67) and an apoptosis marker (cleaved caspase-3) on liver sections from 4 week old 
TAK1LPC-KO and WT mice revealed proliferation and to a lesser extent apoptosis of 
cholangiocytes in livers of TAK1LPC-KO mice which was similar in hepatocytes (Figure 11A-E, 
12A-E, and Figure 25). This shows that TAK1 seems to have an important regulatory function 
in mediating apoptosis and proliferation in cholangiocytes as well as in hepatocytes. 
Moreover, the detection of apopototic cholangiocytes in 4 week old TAK1LPC-KO mice might 
indicate that these animals begin to lose their bile duct epithelial cells at the age of 5 to 6 
weeks (Figure 24 A-D). To clarify this point performing of pan-cytokeratin stainings from 3 
to 4 week old TAK1LPC-KO liver tissues would be useful. 
Additionally, the representative ultrastructural picture of abnormal bile canaliculus found in 
the liver of a 8 week old TAK1LPC-KO mouse maintain the important function of TAK1 in liver 
parenchymal cells (Figure26). 
In future in vitro experiments would be helpful to obtain more information about the specific 
function of TAK1 in cholangiocytes and the associated molecular pathways. Techniques are 
well established to isolate primary cholangiocytes from rat livers, but as discussed with Prof. 
Dr. Nicolas LaRusso and his colleagues (Mayo Clinic College of Medicine, Rochester, 
Minnesota), it is a considerable expenditure to achieve high yields of cholangiocytes. 
According to the small size of mouse liver, it would be a very difficult process to achieve 
appropriate amounts of freshly isolated primary cholangiocytes from mouse livers.  
Thereby, we tried to circumvent this problem by using laser capture microdissection (LCM) 
technique, dissecting cholangiocytes from WT and TAK1LPC-KO livers. Transcriptional 
analysis of Sca-1, Claudin-7, and Epcam, characteristic markers for oval cells and intrahepatic 
biliary epithelial cells showed strong upregulation in cholangiocytes/oval cells from WT and 
TAK1LPC-KO mice compared with laser-dissected WT hepatocytes (Figure 27), confirming the 
specificity of this appraoch. We showed that on transcriptional level Tak1 expression was 
approximately 3-fold downregulated in cholangiocytes/oval cells from TAK1LPC-KO mice as 
compared to WT cholangiocytes/oval cells (Figure 27) which indicated efficient deletion of 
Tak1 in these cells. Similar to previous data from whole liver extracts (Figure 13), mRNA 
expression of Afp was on average approximately 7 times higher in TAK1LPC-KO livers as 
compared to WT cholangiocytes/oval cells (Figure 27). In contrast, the NF-κB target gene 
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A20 was downregulated on average 2.4 fold in cholangiocytes/oval cells of TAK1LPC-KO livers 
when compared to WT cholangiocytes/oval cells (Figure 27). These results suggest that in 
addition to hepatocyte specific effects, cholangiocyte specific effects of Tak1 ablation also 
contribute to ductopenia in TAK1LPC-KO mice and furthermore the deletion of Tak1 in 
cholangiocytes/oval cells influences similar pathways and transcriptional targets as in 
hepatocytes. In TAK1LPC-KO biliary epithelial cells, NEMO seems to control pro-apoptotic 
signalling pathways independently of NF-κB. Furthermore, in hepatocytes with functional 
TAK1, NEMO acts as a tumour-suppressor in liver parenchymal cells by activating NF-κB 
and preventing spontaneous caspase-8 and caspase-3 dependent hepatocyte apoptosis and 
compensatory proliferation, as demonstrated by hepatocarcinogenesis in 12 month old 
NEMOLPC-KO mice (LUEDDE et al. 2007). However, TAK1 deletion leads to a change in the 
tumour-suppressor function of NEMO causing a switch towards a tumour promoting role, as 
demonstrated by the massive dysplasia and early development of cancer (Figure 14A and B) 
independent of NF-κB. These data argue for a TAK1 dependent effect on NEMO’s function 
in hepatocarcinogenesis.  
Interestingly, the generation of TAK1 mice expressing an alternative albumin-driven Cre 
recombinase (TAK1∆hep) (POSTIC and MAGNUSON 2000) showed similar characteristics as 
noticed in TAK1LPC-KO mice such as hepatocyte hyperplasia and dyspalsia (Figure 29A-C). 
However, serological analysis revealed mild hyperbilirubinemia and only slightly elevated 
ALT and AST levels in these animals (Figure 29D), contrary to the strongly elevated bilirubin 
and ALT and AST levels detected in the serum of TAK1LPC-KO mice (Figure 5C). H/E and 
A6+ stained liver sections from 9 week old TAK1∆hep mice displayed areas of ductopenia 
within some portal tracts (Figure 29E). On the other hand, some periportal areas in 
TAK1∆hep mice showed several A6+ stained hepatocytes suggesting that they originated 
from A6+ oval cells (Figure 29E). Increased abundance of immature hepatocytes in 
TAK1∆hep animals was supported by decreased mRNA expression levels of epithelial 
markers such as Albumin and c/ebp-β (Figure 29F). These data indicated that in some areas, 
hepatocyte dysplasia and hyperplasia might have an impact on biliary integrity in TAK1∆hep 
as well as in TAK1LPC-KO mice. Based on the increased spontaneous apoptosis rate of 
hepatocytes in TAK1LPC-KO mice it is conceivable that the oval cell compartment is activated 
to counteract the massive hepatocyte death. Simultaneously there is also an enhanced loss of 
cholangiocytes which is also compensated by oval cell transdifferentiation into 
cholangiocytes. In this prolonged process of oval cell activation and transdifferentiation into 
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hepatocytes or cholangiocytes it might be possible that there is a shift in focusing mainly on 
hepatocyte regeneration in order to maintain liver function. 
Finally, it has been shown that in addition to hepatocytes the albumin-cre line can also lead to 
leaky expression of Cre-recombinase in intrahepatic cholangiocytes (XU et al. 2006), 
implying that not only hepatocyte specific effects of TAK1 deletion influence the phenotype 
in TAK1∆hep mice. 
Beside the TNFR signalling pathway, we also tested if other signalling cascades including the 
IKK-complex are involved in tumourigenesis. We showed that the activation level of the 
Forkhead transcription factor FOXO3a, which is under regulation of Akt and plays an 
important role in cell-cycle arrest (DIJKERS et al. 2000; FURUKAWA-HIBI et al. 2002; MEDEMA 
et al. 2000), DNA repair (FURUKAWA-HIBI et al. 2002; TRAN et al. 2002) cellular 
proliferation, metabolism, apoptosis (BRUNET et al. 1999; DIJKERS et al. 2002; KAESTNER et 
al. 2000), and cellular stress (BRUNET et al. 1999; ESSERS et al. 2004; FURUKAWA-HIBI et al. 
2002) was increased (Figure 23). Thereby, we provided evidence for a possible role of IKK-
dependent activation of FOXO3a in heptocarcinogenesis in TAK1LPC-KO mice (Figure 23). 
Although it is presently not conclusive how the enhanced activation of FOXO3a is mediated 
in TAK1 deficient livers, but the data from Mihael Vucur might indicate that this process is 
mediated in an IKK-dependent way. Recent studies have demonstrated direct interactions 
between TAK1 and other FOXO proteins triggered by NEMO-like kinase (NLK) (KIM et al.) 
and JNK (ESSERS et al. 2004; LEE et al. 2008). To elucidate the exact molecular interactions 
between TAK1 and FOXO3a and the functional role of FOXO3a in the TAK1LPC-KO tumour 
model more genetic studies are required.  
 
 
4.6 TAK1 ablation in LPC affects chromosomal integrity  
 
Histological analysis of H/E, cytokeratin and reticulin staining on liver sections of 25 to 36 
week old TAK1LPC-KO animals revealed increased tumour formation as indicated by loss of 
cytokeratin and the regular reticulin network (Figure 14B).  
These tumours showed striking modifications on chromosome 4, 8 and 13 (Figure 16). A 
similar aberration pattern was oserved. These amplifications and deletions of chromosomal 
regions ranged from 0.68 MB to 151 MB in TAK1LPC-KO tumours. Furthermore, examination 
of the expression levels from 72 established oncogenes and tumour-suppressor genes revealed 
significant upregulations of oncogenes which are mainly located on the above mentioned 
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chromosomes (Figure 17 and Table A2). Surprisingly, the expression level of the classical 
tumour-suppressor gene p53 (Table A2) was not significantly changed in HCCs from 
TAK1LPC-KO mice. Moreover, we demonstrated that TAK1LPC-KO HCCs were highly 
proliferative, whereas NEMOLPC-KO HCCs did not reveal such a high number of proliferating 
cells but more differentiated cells (Figure 18). These findings imply that TAK1 might impact 
chromosomal integrity during cell-cycle progression, particularly with regard to the spindle 
apparatus. This idea provided a reasonable explanation to our findings from Western blot 
analysis. Despite our attempts for equally loaded protein concentrations, we detected always 
less signalling of α-tublin in liver extracts from TAK1LPC-KO mice when compared to 
NEMOLPC-KO and WT liver lysates. This suggests that TAK1 may influence the integrity of α-
tubulin or the components of the cytoskeleton. The most important elements of the spindle 
apparatus are microtubules which are polymers of αβ-tublin dimers. The deletion of TAK1 
could have an impact on microtubules’ structure and finally the spindle apparatus, leading to 
chromosomal aberrations and uneven distribution of the chromosomes. Moreover, the 
chromosomal aberrations detected on chromosome 4, 8 and 13 represent a selective advantage 
for hepatocytes lacking TAK1, caused by significantly increased expression levels of proto-
oncongenes like FgfR1 (chromosome 8), FgR (chromosome 4) and, particularly, Jun 
(chromosome 4), Net1 and Ntrk2 (chromosome 13), which may prevent hepatocyte death. 
Ntrk2 might be a promising candidate for further studies to clarify the role of TAK1 in 
hepatocarcinogenesis, due to its function as a high affinity catalytic receptor for several 
protein growth factors inducing survival and differentiation of distinct cell populations.  
These results suggested that distinct mechanisms leading to hepatocarcinogenesis in TAKLPC-
KO and NEMOLPC-KO mice. Both mouse models displayed defective NF-κB-activation in 
hepatocytes, but only one model showed characteristical chromosomal aberrations within 
certain chromosomal loci, upregulation of individual oncogenes as well as different 
histopathological features. This emphasises that a currently unknown molecular pathway 
downstream of TNF-associated molecules exist, which might connect inflammation with 
specific genetic alterations, representing the basis for malignant transformation of hepatocytes 
(VUCUR et al. 2010). 
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4.7 Relevance for human HCC 
 
In order to achieve a better understanding of the molecular mechanisms of 
hepatocarcinogenesis, several studies were performed on human HCC tissue. However, these 
different studies revealed many genetic and epigenetic alterations (LLOVET and BRUIX 2008). 
As such, chromosomal alterations could be attributed to certain genes potentially involved in 
hepatocarcinogenesis, such as c-Myc (8q), Cyclin A2 (4q), Cyclin D1 (11q), Rb1 (13q), 
AXIN1 (16p), p53 (17p), IGFR-II/M6PR (6q), p16 (9p), E-cadherin (16q), SOCS (16p), and 
PTEN (10q) (LLOVET and BRUIX 2008; VILLANUEVA et al. 2007). Moreover, different 
chromosomal alterations could be detected in HCCs, of which amplifications of 1q (58%-
78%), 6p, 8q, 17q, and 20q, as well deletions of 4q, 8p, 13q, 16q, and 17p represented the 
most frequent incidences (DING et al. 2010; MARCHIO et al. 1997). However, in several cases 
it was problematic to determine whether these alterations represented a correlative 
epiphenomenon or if they were causally linked to HCC pathogenesis. In fact there is raising 
number of gentic and chemical murine models, but the questions remains if all of these 
models have a critical impact and relevance to clarify which molecular pathways are involved 
in human hepatocarcinogenesis. The second important aspect is to decide which experimental 
mouse models reflect best the different types of HCC in patients. This problem could be 
solved by a more systematic approach to evaluate and compare characteristic molecular and 
genetic features between the different murine HCC models. Thereby, chromosomal 
aberrations in the different murine models, histopathology, transcriptional and metabolic 
alterations could be compared at different stages of tumour initiation, promotion and 
correlated with the progression of HCC in cirrhotic transformed livers. In future it would be 
important to examine the contribution of the signalososome and transcriptome in liver cancer 
progression. Moreover, it is also of relevance to clarify if hepatic stems cells have a 
significant impact on the process of tumorigenesis (VUCUR et al. 2010). 
 
 
4.8 Perspectives 
 
In the previous chapters different possibilities were discussed how the deletion of TAK1 
could drive this severe phenotype at the molecular level. Another interesting aspect would be 
to examine if the ablation of TAK1 affects the composition of the complex I of the TNFR 
signalling cascade and its binding partners. After the activation of the TNFR signalling 
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cascade the adaptor protein RIP1 gets K63-ubiquitinated and brings the TAK1-complex 
(TAK1, TAB2/3) and NEMO in spatial proximity, leading to the activation of the IKK-
complex (IKKβ) and subsequently resulting in the nuclear translocation of NF-κB where it 
activates its target genes (ADHIKARI et al. 2007). Despite the deletion of TAK1, it is likely 
that NEMO binds to RIP1 which may lead to a functional gain of these NEMO/RIP1- or 
NEMO/TRAF complexes in hepatocarcinogenesis. This correlates with the finding that 
TAK1PC-KO mice showed a strong increase in MKK4/7 and JNK activation in their livers in 
response to LPS-injection, which might affect dysplasia and carcinogenesis (SAKURAI et al. 
2006). 
Further experiments are needed to proof if NEMO will bind to other proteins than RIP1 and 
TRAFs, thereby changing NEMO’s function as a tumour suppressor through a tumour 
promoter. 
Moreover, ubiquitination is a key regulatory element in activation or termination of signalling 
cascades (CHEN 2005; WANG et al. 2001). Here, it is not clarified if the deletion of TAK1 has 
an impact on the ubiquitination of NEMO or other members of the TNFR signalling pathway 
which may lead to new protein-protein interactions, thereby promoting different features of 
the same protein. 
Additionally, our data revealed the activation of another MAP3K, TAO2, after LPS 
stimulation in both TAK1LPC-KO and NEMOLPC-KO animals. Recent studies as wells as our 
work argue for a functional interaction between the individual MAP3Ks. Therefore, it would 
be possible that during different cellular processes other MAP3Ks like ASK1, MEKK3, or 
TAO2 are getting activated (as shown) and interact with TAK1 or NEMO. Different studies 
demonstrated that oxidative stress, as a result of massive apoptosis, leads to the activation of 
MAP3Ks as well. Thus, the examination of ROS and iNOS levels would elucidate if oxidative 
stress play a role in mediating this phenotype.  
In this present work we showed that TAK1 has a crucial role in mediating early-onset of 
hepatocarcinogenesis associated with biliary ductopenia and cholestasis. TAK1 might also 
receive a gain of function in NEMOLPC-KO mice and may promote procarcinogenic effects 
which will not be detected in the presence of NEMO. Further, examination of NEMO-
dependent functions in hepatocarcinogenesis may reveal potential candidates for prevention 
and treatment of liver cancer. 
Finally, the generation of a LPC knock-out of TAK1 and NEMO (TAK1/NEMOLPC-KO) 
would be helpful to specify the role of NEMO as a tumoursuppressor or tumourpromoter and 
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might leading to a change of viewpoint in the controversial debate on the function of the NF-
κB pathway in hepatocarcinogenesis. 
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5. Summary 
 
The MAP3-kinase TGF-β-activated kinase 1 (TAK1) is activated in response to cytokines like 
TNF-α, TGF-β as well as by the bacterial endotoxin lipopolysaccharide (LPS). TAK1 is 
involved in controlling the activation of p38MAPK, JNK, and NF-κB in various cellular 
systems thereby critically modulating innate and adaptive immune responses and connecting 
cytokine stimulation with activation of inflammatory signalling pathways. After activation of 
the TNF signalling cascade, TAK1 and its adaptors TAB2, TAB3, and NEMO are recruited to 
polyubiquinated RIP1, by which TAK1 phosphorylates and activates the catalytic IKK 
subunits. Although it has been shown that TAK1 is essential for innate and adaptive immune 
responses, its functional role in liver parenchymal cells remains elusive. In the present work, a 
conditional deletion of Tak1 in liver parenchymal cells (hepatocytes and cholangiocytes) was 
generated to investigate the role of TAK1 in the liver and was correlated to the liver 
parenchymal knockout of Nemo. 
The deletion of Tak1 in liver parenchymal cells (TAK1LPC-KO) causes spontaneous 
development of a severe phenotype causing lethal biliary chirrosis. These animals suffer from 
advanced hepatitis and an acute cholangitis at the age of 6 weeks, leading to enhanced 
mortality rate between 14 and 36 weeks of age.  
We showed that TAK1 prevents liver cell apoptosis and hepatic inflammation since it is 
necessary for NF-κB activation but not JNK activation in response to LPS stimulation, a 
potent inducer of TNF secretion from non-parenchymal liver cells. However, qRT-PCR 
analysis revealed that ablation of TAK1 in liver parenchymal cells spontaneously activates the 
TGF-β signaling pathway. This data showed that the TGF-β isoforms 1 to 3 were strongly 
upregulated, correlating with increased SMAD2 activation and upregulation of the matrix 
genes CollagenIα1, Mmp-1, and Mmp-9. Moreover, histological analysis of liver tissues from 
6 week old TAK1LPC-KO mice displayed a strong reduction of biliary epithelial cells compared 
with age-matched WT and NEMOLPC-KO animals. Immunohistochemical stainings of liver 
sections from 3 to 4 week old TAK1LPC-KO mice showed enhanced apoptotis as well 
proliferation of cholangiocytes, indicating that the leakage of cholangiocytes might begin 
between 5 and 6 weeks of age.  
Characterization of liver tumours in 16 to 33 week old TAK1LPC-KO mice revealed an 
intriguing chromosomal signature. More than 85% of all investigated HCCs displayed 
amplifications on the entire chromosome 13 or large portions of it, whereas large 
amplifications on chromosomes 4 and 8 were detected but in a smaller proportion of 
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TAK1LPC-KO livers. In addition, a 16-gene array analysis demonstrated that these tumours 
were highly proliferative active while NEMOLPC-KO HCCs were less proliferative but more 
differentiated. These results showed that the deletion of TAK1 in liver parenchymal cells 
promotes a 5 to 9 month earlier development of HCCs than in NEMOLPC-KO mice.  
In summary, the ablation of TAK1 in hepatocytes and cholangiocytes causes a dramatic 
phenotype which is characterized by dysplasia and an early-onset of HCC coinciding with 
biliary ductopenia and cholestasis. 
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6. Zusammenfassung 
 
Die MAP3-kinase TGF-β-aktivierende Kinase (TAK1) wird durch Zytokine wie z.B. TNF-α, 
TGF-β, aber auch durch bakterielle Lipopolysaccharide (LPS) aktiviert. TAK1 hat eine 
wichtige Kontrollfunktion in Bezug auf die Aktivierung von p38MAPK, JNK und NF-κB in 
verschiedenen Zellsystemen, aber auch in der Regulation der angeborenen als auch der 
erworbenen Immunantwort und stellt ein wichtiges Bindeglied zwischen der Stimulation von 
Zytokinen und der daraus resultierenden Aktivierung pro-entzündlicher Signalwege dar. 
Während der Aktivierung des TNF-Signalweges binden TAK1 und seine Adapter, TAB2 und 
TAB3, als auch NEMO an das polyubiquitinierte RIP1, welches anschließend zur 
Phosphorylierung und somit zur Aktivierung der katalytischen IKK-Unterheinheiten durch 
TAK1 führt. 
Ziel dieser Arbeit war die Untersuchung der spezifischen Rolle von TAK1 in den 
parenchymatösen Zellen der Leber. In diesem Zusammenhang wurden Tiere mit einer TAK1-
Deletion in Hepatozyten und Cholangiozyten generiert (TAK1LPC-KO) und mit den TAK1-
expremierenden Wurfgeschwistern (WT), als auch mit Tieren verglichen, die eine Deletion 
von NEMO (NEMOLPC-KO) in den parenchymatösen Zellen der Leber aufwiesen. 
Die Deletion von Tak1 in den Parenchymzellen der Leber verursachte die Entwicklung eines 
spontanen und sehr massiven Phänotyps, welcher u.a. durch die Entwicklung einer letalen 
biliären Zirrhose gekennzeichnet war. Diese Tiere litten im Alter von 6 Wochen an einer 
fortgeschrittenen Hepatitis und einer akuten Cholangitis, die im weiteren Verlauf tödlich war 
(erhöhte Sterberate im Alter zwischen 14 und 36 Wochen). 
Es konnte gezeigt werden, dass nach Stimulierung der Leber mit LPS, welches zu einer 
erhöhten TNF-Sekretion nicht-parenchymatöser Zellen führt, TAK1 aufgrund seiner 
vermittelnden Aktivierung von NF-κB die Zellen vor Apoptose und proentzündlichen 
Prozessen bewahrte. Des Weiteren konnte durch qRT-PCR gezeigt werden, dass das Fehlen 
von TAK1 zu einer spontanen Aktivierung des TGF-β Signalweges führte. Diese Daten 
offenbarten, dass die drei TGF-β-Isoformen deutlich hochreguliert waren, korrelierend mit 
einer erhöhten SMAD2 Aktivierung und verstärkter Expression verschiedener Matrix-Gene, 
wie z.B. CollagenIα1, Mmp-1 und Mmp-9. TGF-β vermittelt zudem den Prozess der 
epithelialen-mesenchymalen Transition (EMT), welcher an der Entwicklung der primären 
biliären Zirrhose (PBZ) im Menschen maßgeblich beteiligt ist. Weitere qRT-PCRs zeigten, 
dass die Gene Snail1 und Hey, die diesen Prozess hauptsächlich beeinflussen, in den Lebern 
der TAK1LPC-KO Mäuse hochreguliert waren. 
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Die Auswertungen histologischer Schnitte von Lebern 6 Wochen alter TAK1LPC-KO Tiere 
zeigte einen deutlichen Rückgang von Gallengangsepithelzellen im Vergleich zu den Lebern 
der WT und NEMOLPC-KO Tiere. Ferner zeigten immunhistologische Färbungen eine erhöhte 
Apoptose und Proliferation der Gallengangsepithelzellen in Leberschnitten 3 bis 4 Wochen 
alter TAK1LPC-KO Mäuse, was darauf hinweisen könnte, dass der Verlust an 
Gallgangsepithelzellen im Alter von 5 und 6 Wochen einsetzt.  
Die genetische Charakterisierung der Lebertumoren in den TAK1LPC-KO Tieren zeigte eine 
auffallende chromosomale Signatur, da > 85% aller untersuchten Lebertumoren 
Amplifikationen des gesamten Chromosoms 13 oder große Bereiche davon aufwiesen. 
Größere und kleinere Amplifikationen wurden ebenso auf den Chromosomen 4 und 8 
gefunden. Mittels einer 16-Gen-Analyse konnte gezeigt werden, dass diese Tumoren 
hochproliferativ sind. Im Gegensatz dazu konnten die Lebertumoren der NEMOLPC-KO Tiere 
als differenzierter und weniger proliferativ eingestuft werden. Diese Ergebnisse zeigten, dass 
das Fehlen von TAK1 in parenchymatösen Leberzellen zu einer 5-9 Monate früheren 
Entwicklung von Tumoren führte als in den Lebern der NEMOLPC-KO Mäuse. 
Zusammenfassend lässt sich sagen, das die konditionelle Deletion von Tak1 in Hepatozyten 
und Cholangiozyten zu Dysplasien, und zu einer HCC-Frühmanifestation führt, welche durch 
eine biliäre Ductopenie und Cholestase begeleitet wird. 
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Identification number (mouse ID) of wild-type mice (20-23 weeks of age) and quantification of HCC per analyzed mouse liver 
is shown.
Identification number (mouse ID) of NEMOLPC-KO mice (21-26 weeks of age) and quantification of HCC per analyzed mouse liver 
is shown.
 
* These HCC were positive for GP73 in the hepatoid compartment of the HCC but were negative in the clear cell compartment.
-(Foc): negative staining of the tumor in general but very few discrete positive cells in the tumor  
+ / -: positive and negative areas within one and the same tumor 
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Histolological analysis of liver tumors 
Identification number (mouse ID) of TAK1LPC-KO mice (16-33 weeks of age), quantification of HCC per analyzed mouse liver as well as 
histological HCC characteristics are shown. We have divided the cytological variants found in HCC based on the diameter of 
hepatocytes. Small cell: hepatocytes with a diameter < 18 µm. Medium cell: hepatocytes with a diameter from 18 to < 21 µm. Large cell: 
hepatocytes with a diameter > 21 µm. We further defined the HCC growth pattern for clear cell (CL) or hepatoid (Hepa.) changes. Clear 
cell: Broad transparent cytoplasmic rim with strong increase of cytoplasm to nuclear ratio. Hepatoid: Aberrant hepatocytes with 
hepatocyte like phenotype. All described liver tumors were well differentiated HCC. HCC size was quantified in mm. Number of Ki67+
hepatocytes are indicated as Low/ Moderate/ High and abbreviated as: Low, Mod and High. 
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8----Insr21
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8----Jund24
6----kras25
4----Lyn26
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-
-
1,4182E-06
-
-
-
-
-
-
0,017842075
- 17---MAPK28
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2---MEK31
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134,89288E-051,12184E-051,72591E-07Ntrk2
3---Ntrk1
3---nras
8---Nr2f6
139,21827E-050,0168662560,000259481Net1
4---Mycl1
9---mst1
17---msh2
 
Analysis on the transcriptional level of 72 well known oncogenes and tumor-suppressor genes with established correlation to 
carcinogenesis in micro-dissected HCC from TAK1LPC-KO mice. Orange marked genes are significantly up- or downregulated
(indicated by arrows) in t-test or t-test log analysis, while red-marked genes were significantly upregulated in t-test and t-test 
log analysis with Bonferroni-correction. “-” indicates not significantly regulated genes. Chromosomal locations of the 
respective genes are indicated. 7-9 liver specimens (HCC from TAK1LPC-KO mice / WT liver tissue) were analyzed. 
Transcriptional analysis of oncogenes/ tumor-supressor genes
5----c-kit8
t-Test logt-Test
0,049321315
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-
-
-
-
-
-
-
-
-
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-
0,030678859
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p-value 
(significant) raw
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3---Ect2
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2---catenin 1b
Chromosomep-value (significant) Bonferroni-corrected
p-value (significant) 
Bonferroni-correctedp-value (significant) raw
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10not detectablenot detectablenot detectablenot detectableEct2l67
X- chromosomenot detectablenot detectablenot detectablenot detectableElk168
4not detectablenot detectablenot detectablenot detectableMmel169
10not detectablenot detectablenot detectablenot detectablemyb70
4----mos71
12----mycn72
t-Test logt-Test
p-value 
(significant) rawNr. Chromosome
p-value (significant) 
Bonferroni-corrected
p-value (significant) 
Bonferroni-correctedp-value (significant) raw
oncogene / tumor
supressor gene
Abbreviations: 
Abl: Abelson murine leukemia oncogene; Aktip: AKT interacting protein; APC: adenomatous polyposis coli; bcl2: B-cell 
leukemia/lymphoma 2; bcl3: B-cell leukemia/lymphoma 3; bcl6: B-cell leukemia/lymphoma 6; catenin 1b: catenin beta-1; 
cdkn2a: cyclin-dependent kinase inhibitor 2A; c-kit: c-kit proto-oncogene protein; c-myc: myelocytomatosis oncogene; Crkl: v-
crk avian sarcoma virus CT10 oncogene homolog-like; Ect2: ect2 oncogene; Ect2l: epithelial cell transforming sequence 2 
oncogene-like; Elk1: member of ETS oncogene family; ets1: E26 avian leukemia oncogene 1, 5' domain; Fgf10: fibroblast 
growth factor 10; FgfR1: fibroblast growth factor receptor 1; FgfR4: fibroblast growth factor receptor 4; FgR: Gardner-Rasheed
feline sarcoma viral (Fgr) oncogene homolog; Fos: FBJ osteosarcoma oncogene; Fyn: proto-oncogene tyrosine-protein kinase
fyn; Hras: Harvey rat sarcoma virus oncogene 1; ikbkb: inhibitor of kappaB kinase beta; Ing1: inhibitor of growth family, 
member 1; Insr: insulin receptor; Jun: Jun oncogene; JunB: Jun-B oncogene; Jund: Jun proto-oncogene related gene d; kras: 
v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog; Lyn: Yamaguchi sarcoma viral (v-yes-1) oncogene homolog; Maf: avian 
musculoaponeurotic fibrosarcoma (v-maf) AS42 oncogene homolog; Mapk14: mitogen-activated protein kinase 14; mapre2: 
microtubule-associated protein, RP/EB family, member 2; mdm2: transformed mouse 3T3 cell double minute 2; MEK: midkine; 
Mmel1: membrane metallo-endopeptidase-like 1; mos: Moloney sarcoma oncogene; Mpl: myeloproliferative leukemia virus 
oncogene; msh2: mutS homolog 2; mst1: macrophage stimulating 1 (hepatocyte growth factor-like); myb: myeloblastosis
oncogene; Mycl1: v-myc myelocytomatosis viral oncogene homolog 1; mycn: v-myc myelocytomatosis viral related oncogene; 
Net1: neuroepithelial cell transforming gene 1; Nr2f6: nuclear receptor subfamily 2, group F, member 6; nras: neuroblastoma
ras oncogene; NtrK1: neurotrophic tyrosine kinase, receptor, type 1; NtrK2: neurotrophic tyrosine kinase, receptor, type 2; p53: 
transformation related protein 53; PIK3CA: phosphatidylinositol 3-kinase, catalytic, alpha polypeptide; Rab20: RAB20, member 
RAS oncogene family; Rab24: RAB24, member RAS oncogene family; Rab2a: ras-related protein Rab-2A; Rab3a: RAB3A, 
member RAS oncogene family; Rab3b:RAB3B, member RAS oncogene family; Rab3c: RAB3C, member RAS oncogene
family; Rab42: RAB42, member RAS oncogene family; Rab4a: RAB4A, member RAS oncogene family; Rab8a: RAB8A, 
member RAS oncogene family; raf1: v-raf-leukemia viral oncogene 1; Rala: v-ral simian leukemia viral oncogene homolog A 
(ras related); Rela: v-rel reticuloendotheliosis viral oncogene homolog A (avian)/p65-NF-kappaB; Ror2: receptor tyrosine 
kinase-like orphan receptor 2; Ros1: Ros1 proto-oncogene; rsu1: Ras suppressor protein 1; Ski: ski sarcoma viral oncogene
homolog (avian); Slc6a3: solute carrier family 6 (neurotransmitter transporter, dopamine), member 3; src: Rous sarcoma 
oncogene; Tfdp1: transcription factor Dp 1; Thrb: thyroid hormone receptor beta; tsc2: tuberous sclerosis 2; Usp4: ubiquitin
specific peptidase 4; Vav3: vav 3 oncogene
8----Rab2043
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6----raf152
13----Rala53
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13----Ror255
10----Ros156
2-0,036527767-0,029152256rsu157
4----Ski58
13----Slc6a359
2-0,038227468-0,008012372src60
8----Tfdp161
10-0,001322372-0,007234169Thrb62
17----tsc263
t-Test logt-Test
not detectable
-
-
p-value 
(significant) raw
9---Usp464
3---Vav365
2not dete tablenot dete tablenot detectableAbl66
Nr. Chromosomep-value (significant) Bonferroni-corrected
p-value (significant) 
Bonferroni-correctedp-value (significant) raw
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A 
Alb        albumin 
AFP        α-fetoprotein 
ALT        alanine transaminase 
AP-1        activator protein 1 
APS        ammoniumpersulfate 
ASH        alcoholic steatohepatitis 
AST        aspartate transaminase 
ATP        adenosine triphosphate 
 
B 
BAFF        B-cell activating factor of the TNF  
Family 
BrdU        bromodesoxyuridine 
BSA        bovine serum albumin 
 
C 
Caspase       cysteine-aspartic proteases 
CK        cytokeratin 
Con A        concavalin A 
Cre        causes recombination 
 
D 
DAPI      4´,6- Diamidino- 2- phenylindole dihydrochlorid 
DEN        dimethlynitrosamine 
ddH2O        distilled water 
DN        dysplastic nodule 
DISC        death-initiating signalling complex 
DNA        deoxyribonucleic acid 
dNTP        deoxyribonucleosid triphosphate 
DMEM       Dulbeccos minimum essential  
Medium  
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DTT        dithiothreitol 
 
E 
EBSS        Earle’s balanced salt solution 
EC        endothelial cell 
ECM        extra cellular matrix 
EDTA        ethylenediaminetetraacetic acid 
EMSA        electrophoretic mobility shift  
assay 
EtOH        ethanol 
 
F 
FADD        Fas-associated death domain  
protein 
FCS        fetal calf serum 
 
G 
g        gram 
 
H 
h        hour 
HSC        hepatic stellate cells 
HCB        hepatitis B virus 
HCC        hepatocellular carcinoma 
HCV        hepatitis C virus 
HRP        horseradish peroxidase 
 
I 
Ig        immunoglobulin 
IL        interleukin 
IκBα        inhibitor of κB chain α 
IKK        IκBα-kinase 
i.p.        intraperitoneal  
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J 
JNK        c-JUN N terminal kinase 
 
K 
kb        kilobase 
kDa        kilodalton 
 
L 
l        litre 
LCM        laser capture microdissection 
L-PK        L-isoform of pyruvate kinase 
LPCKO       liver parenchymal knockout 
LPS        lipopolysaccharide 
LTβR        lymphotoxin-β–receptor 
 
M 
MAPK       mitogen-activated protein kinase 
MMP        matrix metalloproteinase 
M2-PK       M2 isoform of pyruvate kinase 
µ        micro 
mRNA       messenger ribonucleic acid 
 
N 
NASH        non-alcoholic steatohepatitis 
NEMO       NF-κB essential modifier 
NF-κB        nuclear factor kappa light chain  
enhancer of activated B cells 
NIK        NF-κB inducing kinase 
NO         nitric oxide 
NOS         nitrogen species 
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P 
PBS        phosphat-buffert saline 
PCNA        proliferating cell nuclear antigen 
PCR        polymerase chain reaction 
PDGF         platelet-derived growth factor 
PFA        paraformaledahyde 
 
R 
RIP1        receptor interacting protein 1 
RNA        ribonucleic acid 
ROS         reactive oxygen species 
rpm        revolutions per minute 
 
S 
SDS        sodium dodecyl sulfate 
SMAD       small mother against  
decapentaplegic 
STAT3       signal transducer and activator of  
transcription 3 
 
T 
TAE        Tris-Acetat-EDTA-buffer 
TBE        Tris-Borat-EDTA-buffer 
TBS        Tris-buffered saline 
TEMED       N,N,N´,N´- 
Tetramethylethylendiamin 
TGF-β        transforming growth factor-β 
TIMP      tissue inhibitor of  
metalloproteinase 
TLR         toll-like receptor 
TNF-α        tumour necrosis factor-α 
TNFR        tumour necrosis factor receptor 
TRADD       TNFR1-associated DEATH  
Domainprotein      
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TRAF        TNF-receptor associated factor 
TUNEL        terminal deoxynucleotidyl transferase  
dUTP-mediated nick end labelling 
 
U 
UV        utraviolett 
 
W 
WT        wild-type 
 
Z 
ZO-1        Zonula Occludens-1 
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